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Abstract 
Antibiotics have been used in animal feed to promote weight gain, improve feed 
efficiency, and control disease since the 1950s.  Concerns about antibiotic resistance have 
increased since the widespread use of in-feed antibiotics began, but a clear connection between 
antibiotic use in animals and adverse human health effects has not been established.  
Understanding the mechanisms behind antibiotic growth promoters is an important step in 
determining the safety of in-feed antibiotics.  Our study tested the hypothesis that diets with 
virginiamycin would increase intestinal surface area and nutrient processing capacity compared 
with diets without virginiamycin.  Littermate barrows with similar body weight (n=72; 23.0±1.3 
kg; 9 weeks of age) were randomized to pens and pens were randomized to one of three 
treatment groups (0, 11, or 27.5 mg virginiamycin/kg corn-soybean diet).  Within each pen, pigs 
were further randomized to a time point (7 or 14 days).  Intestinal samples were obtained for 
assessment of gross morphology, histomorphology, immunohistochemistry, biochemical 
measurements, disaccharidase activity, and nutrient and ion transport.  Analysis of variance was 
used to statistically analyze the data using the Mixed Model of SAS fitted with a split plot design 
(treatment as the whole plot and time as the subplot).  Preplanned contrasts between 
virginiamycin and control groups were completed.   Pigs fed diets supplemented with 
virginiamycin gained an average of 10% more weight per day with about 12% better feed 
conversion compared with control.  Virginiamycin impacted intestinal functional capacity to a 
greater extent than structural indices.  Glutamine and arginine transport were increased 2-fold in 
the jejunum of virginiamycin fed pigs compared with control (p=0.010, p=0.046, respectively).  
Ileal carbachol induced chloride secretion was lower at day seven, but it increased over time with 
virginiamycin resulting in increased secretion at day fourteen with virginiamycin compared with 
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control (p=0.017).  Virginiamycin directly impacted proximal gut nutrient transport with a more 
delayed response in the distal gut by providing protection against loss in nutrient transport and 
secretory capacity.  Increased nutrient transport was observed without increases in absorptive 
surface area indicating that increased functional capacity may be a mechanism by which 
antibiotic promote growth.  Increasing our knowledge on the mechanisms behind antibiotic 
growth promoters will help direct government policy on antibiotic use in animals. 
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Chapter 1: Introduction and Literature Review 
Antibiotics have been used in animal feed to promote weight gain and feed efficiency for 
over 60 years.  Antibiotics can be defined as naturally occurring substances produced by yeasts, 
molds, and other microorganisms that, at low concentrations, suppress or inhibit the growth of 
microorganisms (Cromwell, 2002).  In 1949, it was discovered that “mash” fermented with 
Streptomyces aureofaciens increased the growth of chickens (Stokstad et al., 1949).  The 
fermentation product was found to contain the antibiotic chlortetracycline, which was identified 
to be responsible for the growth response.  Similar growth responses were demonstrated in pigs 
soon after (Cunha et al., 1949; Jukes et al., 1950; Lepley et al., 1950; Luecke et al., 1950).  
Further developments revealed a few parts per million (ppm) of antibiotics in diets were effective 
(Jukes, 1955) and, thus, began widespread use of in-feed antibiotics for growth promotion, feed 
efficiency, and disease control in livestock and poultry. 
Since the widespread use of antibiotics began, there has been increased concern about the 
development of antibiotic resistance.  Although it has been debated for years, in-feed antibiotics 
have been proposed to result in resistant bacteria with the potential to be transferred to human 
pathogens.  The concern of antibiotic resistance has led to political involvement all over the 
world including the banning of in-feed antibiotic use in the European Union.  Political focus in 
the United States has increased since the banning of antibiotic growth promoters in the European 
Union.  Antibiotics continue to play a large role in animal health and production.  Discussions of 
banning such substances have been increasing and it is important to understand the most safe and 
effective use of growth promoting antibiotics.  An understanding of the mechanism(s) behind 
antibiotic growth promoters is essential to better assess antibiotic resistance and its potential 
impact on human health. 
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Antibiotic Growth Promoters 
Antibiotics have been used as growth promoters for years because of the improvement in 
animal weight gain, feed efficiency, and performance.  Antibiotics used for growth promotion 
are given at sub-therapeutic levels and are usually given for an extended period of time.  
Research demonstrating the effectiveness of antibiotics as growth promoters is well documented.   
Cromwell (2002) reported values from data compiled up to 1985 on antibiotic-feed pigs in 
reviews by Hays (1981) and Zimmerman (1986).  Dietary supplementation with antibiotics 
improves average daily gain by an average of 16.4% and feed per unit of gain by 6.9% during the 
starter period (Cromwell, 2002).  Antibiotics fed during the grower period resulted in an average 
increase of 10.6% in average daily gain and a 4.5% decreased in feed per unit of gain (Cromwell, 
2002).  Improvements averaged over the entire grower-finisher period were 4.2% for average 
daily gain and 2.2% for feed per unit of gain (Cromwell, 2002; Figure 1.1).  In-feed antibiotics 
also improve sow performance and can increase farrowing rate up to ten percent (Zimmerman, 
1986).  Currently, over 81% of pig production sites for grower-finisher pigs use in-feed 
antibiotics and almost 33% of sites use in-feed antibiotics continuously (USDA, 2007).   
 
Virginiamycin and Swine Performance 
Several antibiotics are used for growth promotion in animals, but, for the purpose of this 
review, the focus will be on virginiamycin use in swine.  Virginiamycin (trade name: Stafac®) 
has been used in animals as a growth promoter for many years.  Virginiamycin was approved in 
1975 for use in turkeys, swine, cattle, and chickens in the United States (FDA, 2004).  
Virginiamycin has been shown to improve average daily gain by 11%, 10.7%, and 5.7% in 
starter, grower, and finisher pigs, respectively, and feed per unit of gain by 5%, 6.6%, and 3.3%, 
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respectively (Hays, 1981).  Zimmerman (1986) also reported improvements with virginiamycin 
in his review.  In that report, virginiamycin improved average daily gain by 8% and feed per unit 
of gain by 3.6% in starter pigs and average daily gain by 2.5% and feed per unit of gain by 1.4% 
in grower-finisher pigs (Zimmerman, 1986). 
Virginiamycin has continued to be an effective growth promoter in pigs.  Lewis and 
Giesemann (1991) reported significant improvements in daily gain (5.8%) and feed efficiency 
(3.5%) when virginiamycin was feed at 11 mg/kg diet to grower pigs for six weeks but no 
significant differences when fed at 5.5 mg/kg diet for nine weeks during the finishing period.  
Schinckel (1993) found significant improvements in daily gain and feed conversion during 
growing-finishing periods when pigs were fed diets supplemented with 20 mg/kg of 
virginiamycin during the grower period and 10 mg/kg during the finisher period.  Virginiamycin 
improved daily gain by 7.7% and 2.9 to 3.5% in grower and finisher periods, respectively, and 
improved feed per unit of gain by 6.5% and 2.4 to 3.1% in grower and finisher periods, 
respectively (Schinckel, 1993).  Virginiamycin improved feed conversion in grower (1.4%; 
Gaines et al., 2005) and finisher pigs (4.6 to 10.4%; Gramm et al., 2006) when supplemented at 
11 mg/kg diet.  Gramm and colleagues (2006) also reported a trend toward improved weight gain 
(6.4 to 12%) in finisher pigs fed a diet supplemented with 11 mg/kg of virginiamycin.  Percent 
improvements in weight gain are greater than those of feed per unit of gain.  This may suggest 
that feed intake is increased in pigs consuming antibiotics, but improvements in weight gain and 
feed efficiency are observed without increases in daily feed intake (Gramm et al., 2006; Harper 
& Kornegay, 1983; Lewis & Giesemann, 1991; Schinckel, 1993; Stahly et al., 1980). 
Dietary supplementation with virginiamycin also improves sow performance.  
Virginiamycin increases sow body weight at each farrowing, decreases sow weight loss from 
4 
 
farrowing to weaning, and decreases time between weaning to conception (Kantas et al., 1998; 
Kyriakis et al., 1992).  Kyriakis and colleagues (1992) observed increases in milk fat content in 
sows fed virginiamycin.  Virginiamycin, fed at levels of 20, 40, and 60 mg/kg diet from six 
months of age through three breeding cycles, increased both blood cholesterol and total lipids 
concentration in sows during each pregnancy, farrowing, and weaning and improved milk quality 
during the third lactation by increasing fat, protein, lactose, and total solids content (Alexopoulos 
et al., 1998).  Virginiamycin fed at these three levels also increased litter size, birth weight, 
number of piglets weaned, and piglet weaning weight (Kantas et al., 1998; Kyriakis et al., 1992).  
Virginiamycin is effective in market pigs and at other stages of swine production. 
 
Antibiotic Resistance 
Concerns about bacterial resistance began to arise shortly after the performance benefits 
of in-feed antibiotics were discovered.  Resistance became a new concept when descriptions of it 
were published in 1960 in Japan (Akiba et al., 1960).  The increased concern about development 
of resistance started a movement against use of antibiotics in animal feed around 1967 (Jukes, 
1972).  Concerns about adverse human health effects associated with antibiotic use in animals 
were brought about worldwide when a report by The Joint Committee on the Use of Antibiotics 
in Animal Husbandry and Veterinary Medicine was issued to the British Parliament (Chowdhury 
et al., 2009).  That report, known as the Swann Report, proposed that antibiotics used for growth 
promotion should be limited to those that make a significant economic difference in livestock 
production, have little or no application as therapeutic agents in humans or animals, and/or do 
not impair efficacy of a prescribed therapeutic drug through development of resistant strains 
(Swann, 1969).  It was almost 30 years after the movement began before there was global 
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interest or surveillance on the public health impact of antibiotic use in animals (WHO, 1997).  
Research has shown an increase in antibiotic resistance in humans and the plausibility of transfer 
of resistant bacteria from animals to humans; however, substantial data are lacking on how much 
this is a consequence of antibiotic use in animals and if it has a significant effect on human 
health. 
 
Government Regulations   
World Organizations 
A 1969 Report of the Joint Committee on the Use of Antibiotics in Animal Husbandry 
and Veterinary Medicine, commonly known as the Swann Report, reported that antimicrobial use 
in food-producing animals poses a hazard to human and animal health.  In the report, a 
recommendation was made to only use antibiotics that are not used as therapeutic agents in 
humans or animals in animal feed (Swann, 1969).  In 1970, a FDA task force report 
recommended antimicrobial drugs used in human medicine should meet certain guidelines to be 
used for growth promotion (FDA, 1970).  This report led to a code of federal regulations that 
required companies to submit research demonstrating their product does not promote bacterial 
drug resistance (FDA, 2000).  The FDA proposed to withdraw approvals for sub-therapeutic uses 
of penicillin and tetracycline in animal feed due to safety issues; however, reports from the 
National Academy of Sciences in 1980 and the Institute of Medicine in 1988 showed there was 
limited epidemiological research and a lack of direct evidence to either prove or disprove the 
safety of these antibiotics (FDA, 2012a). 
Almost a decade later, the World Health Organization (WHO) issued a report in which 
they concluded all uses of antimicrobials led to selection of resistant bacteria and stated a low 
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dose over a longer period of time is more likely to lead to resistance than higher doses over a 
short period of time (WHO, 1997).  The WHO also reported antibiotic resistance has adverse 
effects on human health and steps should be taken towards a more responsible use of antibiotics 
in animals (WHO, 1997).  The United States government accountability office (GAO) published 
a report in 1999 stating that the extent to which bacterial resistance, as a result of antibiotic use 
in animals, has led to human illness or death could not be estimated at that time (GAO, 1999). 
The Food and Agriculture Organization (FAO), the World Organization for Animal 
Health (OIE), and WHO concluded in 2003 there was accumulating evidence of adverse human 
health effects due to resistant bacteria from antimicrobial use in animals, the food borne route is 
the major route of transmission, and the consequences are most severe when the antibiotics are 
critical to humans (FAO, 2003)  Also in 2003, the Institute of Medicine (IOM) recommended the 
FDA ban all antibiotics used for growth promotion that are in the same class as antibiotics used 
in human medicine (IOM, 2003).  
In 2004, FAO, OIE, and WHO released a second joint report recommending the 
establishment of a list of antibiotics deemed critically important to human health.  The report 
also suggested that good agricultural practices could eliminate the need for in-feed antibiotics 
and expressed the necessity for resistance surveillance systems (FAO, 2004).  A 2004 GAO 
report was similar to the second joint report by the FAO, OIE, and WHO.  GAO recommended 
the FDA expedite risk assessments of critically important antibiotics to determine if use of those 
antibiotics should be prohibited in animals and that the Secretary of Agriculture and Health and 
Human Services develop a plan for collecting data on antibiotic use in animals (GAO, 2004).  
The American Academy of Microbiology published a report in 2009 stating that “resistance is a 
natural phenomenon that cannot be eliminated” and recommended an approach to find new ways 
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to deal with current resistance and try to control future resistance by prudent and responsible use 
of antibiotics in animals (American Academy of Microbiology, 2009).  In 2011, the WHO wrote 
a report which included recommendations to eliminate the use of antibiotics for growth 
promotion and require a veterinary prescription for antibiotic use while only using antibiotics 
deemed critically important for humans when justified (WHO, 2011). 
 
Current Documents in the United States 
The FDA has written Guidance for Industry (GFI) documents regarding antimicrobial 
drug use in food-producing animals.  These guidance documents contain non-binding 
recommendations and are intended to help the industry or sponsors develop products which are 
considered safe in regards to human health.  The FDA currently uses GFI #152 regarding 
approval of new antimicrobial drugs for use in animals.  The FDA must determine that the drug 
is safe and effective for its intended use in the animal and that it is safe with regard to human 
health (FDA, 2000).  The FDA defines a drug as “safe” if there is reasonable certainty of no 
harm to human health from the drug’s use in food-producing animals (FDA, 2003).  
Responsibility falls upon the sponsor to provide sufficient evidence of the drug’s safety for the 
FDA to review and either approve or deny its use. 
The recommendations from the WHO in 2011 are reflected in the most recent FDA 
publications.  The FDA’s Center for Veterinary Medicine published a final guidance document 
on April 13, 2012 that describes the rising concern for antimicrobial resistance in humans and 
steps which can be taken to reduce this risk from antibiotic use in animals (FDA, 2012a).  GFI 
#209 recommended two additional principals about the appropriate or judicious use of medically 
important antimicrobial drugs in food-producing animals which were not included in GFI #152.  
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These principles include voluntary adoption of the use of these drugs be limited to those uses that 
are considered necessary for assuring animal health and that antimicrobial use include veterinary 
oversight or consultation (FDA 2012a). 
Antimicrobial drugs for use in feed or water approved prior to 1993 may have been 
approved for over-the-counter use.  Most antimicrobial drugs for use in food-producing animals 
approved after 1993 must have a veterinary prescription or veterinary feed directive (FDA, 
2012b).  In the draft of GFI #213, the FDA recommends drug sponsors voluntarily revise the 
conditions of use for drugs approved prior to 1993.  The FDA states their approach in the 
guidance document is based on the potential of increased bacterial exposure to antimicrobial 
drugs leads to a greater risk of bacterial resistance (FDA, 2012b). 
 
Government regulation outside the United States 
The recommendations are similar from the “Swann Report” in 1969 to the FDA’s GFI in 
2012 (Table 1.1).  Several countries outside the United States have eliminated the use of 
antibiotics for growth promotion.  Sweden banned the use of all antibiotics for growth promotion 
in animals in 1986 (Butaye et al., 2003).  Norway prohibited the use of virginiamycin in 1998 
and Denmark banned it in 1999 (Butaye et al., 2003).  The European Union banned avoparcin in 
1997, bacitracin, spiramycin, tylosin, and virginiamycin in 1999, and passed regulation for the 
phasing out of the use of all antibiotics for growth promotion in farm animals in 2003 
(Regulation 1831/2003).  The European Union ban on all antibiotics used for growth promotion 
went into effect on January 1, 2006. 
These bans were taken as precautionary steps to the possible risk of antibiotic use in 
animals leading to adverse human health consequences.  Attention has focused mainly on 
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consequences of using of antibiotic growth promoters, but little attention has been given to the 
contrary: what are the consequences of discontinuing antibiotic use for growth promotion?  
Some studies have indicated that bacterial illness rates and resistance levels in humans have 
increased since the ban in Europe (Hayes & Jensen, 2003).  Cox (2005) developed a Rapid Risk 
Rating Technique (RRRT) which is a multiplicative, top-down approach that starts with data on 
the number of clinical cases per year and assesses the estimated fraction that would be prevented 
by interventions.  This technique was developed to estimate the impact that antibiotic use in 
animals has on rates of adverse human health effects; it can be viewed as a risk/benefit analysis 
of continued use of antibiotics (Cox, 2005).  Based on the results from the RRRT, Cox 
concluded that the expected human health benefits from continued virginiamycin use are much 
larger than the expected human health risks (Cox, 2005).  This risk assessment was based on 
virginiamycin use in chickens but is estimated to amplify the results if cattle and pigs were 
included. 
 
Resistance to Streptogramins 
Virginiamycin belongs to the antibiotic class Streptogramins.  Quinupristin-dalfopristin 
(QD; trade name: Synercid®) is a semi-synthetic antibiotic which belongs to the same class as 
virginiamycin.  Synercid® was approved for use in the United States in 1999 for treatment of 
Enterococcus faecium infections in humans and Staphylococcus aureus and Streptococcus 
pyogenes skin and soft tissue infections (FDA, 2004).  Vancomycin is the antibiotic most 
frequently used to treat E. faecium infections in humans (Cox, 2005).  In cases where E. faecium 
expresses vancomycin resistance genes, QD may be used to treat vancomycin-resistant E. 
faecium (VREF; Cox, 2005).  QD is considered critically important for human medicine by the 
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WHO (WHO, 2007) and highly important by the FDA (FDA, 2003).  Concerns exist that animals 
given virginiamycin may produce Streptogramin resistant E. faecium (SREF) strains that will 
colonize or transfer genes to enterococci of the human intestine and lead to treatment failures 
(Bafundo et al., 2003). 
Streptogramin resistance was first reported in staphylococci in 1962 (Butaye et al., 2003).  
The Center of Veterinary Medicine conducted a virginiamycin risk assessment investigating 
Streptogramin resistance in E. faecium attributable to the use of Streptogramins in animals 
(FDA, 2004).  The FDA began the risk assessment in 2000 and released a draft in 2004, but a 
final document was never published.  The  FDA’s preliminary conclusions in the draft included: 
(1) SREF has been found in poultry and swine from the United States and Europe and appears to 
be related to the usage of virginiamycin on farms; (2) resistant bacteria has been found on food 
animal products from retail sources; (3) resistance occurs at low frequencies in the non-
hospitalized population; (4) transfer of resistance from animal to human via food is biologically 
plausible but the extent cannot be currently estimated; and (5) SREF isolates from animals are 
associated with high level resistance but not in humans (FDA, 2004).  The FDA also calculated 
risk assessments for the population and reported that if 10% of resistant-E. faecium is a result of 
virginiamycin use in animals, a person in the United States has an estimated 14 in 100 million to 
7 in 1 billion chance of having impaired Synercid® therapy.  If 100% of resistant-E. faecium 
result from virginiamycin use in animals, the estimated number of impaired Synercid® therapy 
cases would increase 10-fold (FDA, 2004).  
Research investigating the prevalence of virginiamycin-resistant bacteria in swine in the 
United States is limited.  European studies have demonstrated resistance to streptogramins in up 
to 60% of isolates from poultry, swine, and cattle, whereas, Australian studies have observed 
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only a 10 to 20% rate of resistant bacteria (Kieke et al., 2006).  Some studies have shown a 
decrease in virginiamycin-resistant E. faecium in broilers in Denmark after the banning of 
antimicrobial growth promoters (Aarestrup et al., 2001; Emborg et al., 2003).  Resistance may 
occur within the animal and in isolates obtained from the animal, but it can also occur in water 
run-off from production farms.  Sapkota and colleagues (2007) observed a higher percentage of 
virginiamycin resistant enterococci isolated from surface waters down-gradient from a swine 
facility compared with up-gradient from the facility.  
The risks of either banning or continued use of virginiamycin on human health have not 
been fully evaluated.  While there are indications that antibiotic use in animals could potentially 
have adverse human health effects, there is not a clear, definite connection between antibiotic use 
in animals causing critical human illness.  It is vital to keep investigating the relationship 
between antibiotic use in animals and human health.  An important component is to better 
understand the mechanisms by which antibiotics promote growth.   
 
Streptogramins Mechanism of Action 
Virginiamycin belongs to the class Streptogramins that are naturally occurring 
compounds produced predominately by members of the genus Streptomyces (FDA, 2004).  
Streptogramins include two types, A and B, and virginiamycin is a mixture of both components 
termed virginiamycin M and virginiamycin S, respectively.  Individually the A and B 
components only cause bacteriostasis, but together they are bactericidal (Abou-Youssef et al., 
1979; Butaye et al., 2003).  Virginiamycin binds to bacterial 23S rRNA of the 50S ribosomal 
subunit, interfering with peptidyltransferase activity and inhibiting protein synthesis, resulting in 
cell death (Cocito et al., 1997; FDA, 2004).  The A component inhibits the elongation phase in 
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ribosomal assemblage of the protein by interfering with peptidyltransferase function and triggers 
a conformational change in the ribosome which increases binding affinity for component B 
(Bouanchaud, 1997; Cocito et al., 1974).  The B component prevents extension of polypeptides 
and induces detachment of incomplete protein chains (Chinali et al., 1988).  Streptogramins have 
a narrow-spectrum including gram positive bacteria (mainly staphylococci, streptococci, and 
enterococci) and some gram negative cocci.  Most gram negative bacteria are naturally resistant 
due to impermeability of their cell wall (Butaye et al., 2003; Goto et al., 1992). 
 
Antibiotic Modes of Action for Growth Promotion 
The proposed mechanisms by which antibiotics work as growth promoters are mainly 
described under three categories: metabolic, nutritional, and disease-control effects (Figure 1.2).  
Metabolic processes that are directly influenced by antibiotics fall within the metabolic effect 
category.  Research has shown that antibiotics can increase water and nitrogen excretion, liver 
protein synthesis, and gut alkaline phosphatase and decrease fatty acid oxidation, 
phosphorylation reactions, and bile degradation products (Braude & Johnson, 1953; Brody et al., 
1954; Gaskins et al., 2002; Hash et al., 1964; Moser et al., 1980; Weinberg, 1957). 
The nutrition effect includes several proposed mechanisms (Table 1.2).  One mechanism 
is that antibiotics can cause a shift in the microbial population of the gut, which may increase the 
availability of nutrients to the host.  A second proposed mechanism is the protection against 
thickening of the intestinal epithelium secondary to an immune response to intestinal insult, 
resulting in protection of nutrient absorption capacity (Braude et al., 1955; Henderickx et al., 
1981; Niewold, 2007).  A third mechanism is a reduction in gut mass resulting in lower energy 
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expenditure for gut maintenance; therefore, more energy is available for growth (Braude et al., 
1955; Koong et al., 1982; Webster, 1981).  
The disease-control effect is the most widely accepted theory on how antibiotics promote 
growth in animals.  Early research has focused on this concept.  Evidence noted to support this 
effect is that younger animals, whom are more susceptible to infection, have a greater growth 
response to antibiotics than older animals and growth response to antibiotics is greater when 
hygiene is poor (Visek, 1978).  The disease control effect includes suppressing disease-causing 
organisms and production of bacterial toxins, therefore, inhibition of sub-clinical infections 
(Butaye et al., 2003; Carlson & Fangman, 2000; Cocito, 1979; Feighner & Dashkevicz, 1987; 
Gaskins et al., 2002; Hays, 1981). 
 
Impact on the Microbiota and Microbial Products 
Many of the proposed mechanisms of action relate to changes in the microbiota and, 
therefore, changes in products produced by intestinal microbiota.  Much of the early research has 
focused on changes associated with the intestinal microbiota.  The generally accepted hypothesis 
is that “antibiotics improve efficiency of animal growth via inhibition of normal microbiota, 
leading to increased nutrient utilization and reduction in maintenance costs of the gastrointestinal 
system” (Gaskins et al., 2002). 
Virginiamycin decreases the number of lactobacilli in the upper gastrointestinal tract in 
pigs (Agudelo et al., 2007; Decuypere et al., 1973; Langlois et al., 1978).  Song and colleagues 
(2008) observed a reduction in the total number of bacterial cells in ileal digesta and feces with a 
reduction in some bacterial species in ileal digesta of growing pigs fed diets supplemented with 
virginiamycin.  In vitro data confirm that virginiamycin decreases lactobacilli in gastric and ileal 
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contents (van Assche et al., 1975; Vervaeke et al., 1979).  Lactobacilli are one of the main 
producers of lactic acid, which is the major end product of microbial carbohydrate metabolism.  
Virginiamycin has also been shown to reduce lactic acid production to 30% of control pigs and 
eliminate lactic acid production in vitro (Hedde et al., 1981; van Assche et al., 1975).  A 
reduction in lactic acid indicates a reduction in glucose utilization by gut bacteria, which has 
been demonstrated in vitro (Hedde & Lindsey, 1986).  Langlois and colleagues (1978) found that 
the differences in lactobacilli were not sustained when virginiamycin was removed from the diet.  
These findings indicate that supplementation with virginiamycin has a direct effect on the 
microbiota and result in more glucose available to the pig for digestion and absorption. 
Agudelo and colleagues (2007) observed significant decreases in lactobacilli in ileal 
contents of pigs fed virginiamycin supplemented diets with normal phosphorus content, but they 
did not obverse a reduction in pigs fed a phosphorus-deficient diet supplemented with 
virginiamycin.  They also reported a numerical increase in phytate-utilizing bacteria in 
virginiamycin fed pigs compared with pigs fed diets without virginiamycin in both normal and 
phosphate-deficient diets (12.45% and 17.2%, respectively).  This group is the first to report the 
effect of virginiamycin on phytate-utilizing bacteria. 
Virginiamycin reduced ammonia production by 50% compared with control in vitro (van 
Assche et al., 1975).  Dierick and colleagues (1986) demonstrated that virginiamycin-fed pigs 
had 10% and 15% less ammonia in the small and large intestine, respectively.  Ammonia and 
amines are products of the decarboxylation of amino acids and are toxic, which is not supportive 
of digestion and absorption.  Virginiamycin has been shown to reduce amine production in pigs 
(Henderickx et al., 1993).  Escherichia coli is a gram negative bacterium that is a major producer 
of amines; however, virginiamycin is not active against E. coli.  Henderickx and colleagues 
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(1993) proposed the reduction in amine production is a result of increased acidity mediated by 
lactobacilli.  A reduction in ammonia and amines indicate a reduction in the loss of amino acids 
and, therefore, an increase in amino acids available for the host animal. 
Volatile fatty acid production in gastric and ileal contents has been shown to be 50% 
lower in virginiamycin fed pigs that that of pigs fed diets without virginiamycin (Hedde et al., 
1981; Vervaeke et al., 1979).  Some researchers have shown a slight increase in coliforms in the 
gastrointestinal tracts of pigs fed diets supplemented with virginiamycin (Decuypere et al., 1973; 
Langlois et al., 1978).  However, Vervaeke and colleagues (1979) failed to show a difference in 
coliforms in gastric and ileal contents.  Additionally, differences in coliforms and lactobacilli 
were not sustained when virginiamycin was removed from the diet (Langlois et al., 1978).  These 
findings indicate that antibiotics may have direct, immediate effects on the microbiota that are 
not sustained once removed from the diet. 
 
Impact on Immune Response 
As stated previously, a large portion of the literature has focused on direct antibiotic 
effects on the microbial population and products.  A more recent proposal is a direct effect on the 
immune response with an indirect effect on the microbiota.  Niewold (2007) proposed a concept 
where antibiotics work to permit growth by inhibiting the production and excretion of catabolic 
mediators by intestinal inflammatory cells.  Niewold (2007) believes the changes observed in the 
microbiota are a result of altered conditions of the intestinal tissue.  Niewold supports this theory 
by interpreting previous microbiota studies in a different manner.  Antibiotics accumulate in 
inflammatory cells (Labro, 1998; 2000; van den Broek, 1989), which results in lower levels of 
proinflammatory cytokines and a lower catabolic stimulus; thus, energy is spared in the animal 
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and can be used for growth.  Intestinal inflammation results from the accumulation of 
inflammatory cells in the mucosa and leads to thicker intestinal epithelium.  The thinner 
intestinal tissue cited for improved nutrient absorption could be reduced inflammation resulting 
from reduced influx and accumulation of inflammatory cells (Larsson, 2006).  Therefore, 
Niewold proposed that antibiotics directly impact the immune response with secondary effects 
on the microbiota. 
 
Impact on Rate of Nutrient Passage and Nutrient Digestibility 
Researchers have investigated the influence of antibiotics on rate of passage and 
digestibility of energy, protein, and some minerals.  These variables are commonly viewed as 
secondary effects of antibiotics.  Rate of passage has been studied in virginiamycin fed pigs.  
Fausch (1981) reported the average time of passage was 4 to 11% longer in pigs fed 11 mg/kg of 
virginiamycin for one week compared with control.  This was in agreement with Hedde and 
colleagues (1981) and Ravindran and colleagues (1984) who demonstrated slower passage rates 
(2.6 to 29% longer) in grower and finisher pigs fed virginiamycin.  A slower rate of passage of 
feed through the intestine indicates more time for digestion and absorption that could lead to 
increased uptake and improved feed efficiency. 
Virginiamycin improves apparent digestibility of amino acids in the small intestine of 
pigs by up to 9% compared with controls (Decuypere et al., 1978; Dierick et al., 1986; Stewart et 
al., 2010).  Virginiamycin increased ileal digestibility of nitrogen, lysine, glycine, valine, and 
methionine by 1.4 to 4.8% compared with control (Dierick et al., 1986).  Dierick and colleagues 
(1986) also observed an inhibition of amino acid breakdown in the small intestine and increased 
nitrogen retention.  Digestibility of dry matter and energy are improved in pigs fed diets 
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supplemented with 11 mg/kg of virginiamycin (Agudelo et al., 2007; Lindemann et al., 2002; 
Ravindran et al., 1984).  Increased mineral digestibility and retention have also been shown in 
pigs fed virginiamycin (Agudelo et al., 2007; Lindemann et al., 2002).  Virginiamycin 
supplemented at 11 mg/kg diet has been shown to improve digestibility and retention of 
magnesium, copper, zinc, and manganese by 17 to 45% (Ravindran et al., 1984).  An increase in 
ileal digestibility by 3.3 to 5% has also been demonstrated for calcium, phosphorus, and zinc 
with virginiamycin supplementation in pigs (Agudelo et al., 2007; Lindemann et al., 2002).  
Increased utilization of phosphorus may provide an economic benefit via a reduction in inorganic 
phosphorus required in feed (Agudelo et al., 2007).  Improved digestibility of energy, protein, 
and minerals indicate that pigs fed virginiamycin are able to utilize feed more efficiently and 
able to gain weight at a faster rate than pigs fed diets without virginiamycin. 
 Stewart and colleagues (2010) were the first to investigate amino acid digestibility in 
corn-soybean meal diets.  Grower pigs were fed diets supplemented with 11 or 22 mg/kg of 
virginiamycin for four weeks.  Virginiamycin supplemented at 11 mg/kg diet improved apparent 
ileal digestibility of all indispensable amino acids, except arginine, histadine, and leucin by 2 to 
6.7%.  Virginiamycin also improved apparent ileal digestibility of alanine, proline, and tyrosine.  
Virginiamycin supplemented at 22 mg/kg diet improved apparent ileal digestibility of tryptophan 
and valine during the four weeks of feeding.  These effects were lost in all but lysine and 
tryptophan when virginiamycin was removed from the diet for two weeks (Stewart et al., 2010).  
The loss of effect when virginiamycin is removed for the diet indicates a more direct effect of 
virginiamycin on nutrient digestibility.  Increased amino acid digestibility with virginiamycin 
indicates this may be a mode by which virginiamycin promotes growth in pigs. 
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Impact on Intestinal Structure 
Virginiamycin has been shown to impact the microflora of pigs and influence 
digestibility and rate of passage.  Few studies have investigated the impact of in-feed antibiotics 
on pig intestinal structure.  Only one research project was found in the literature to report 
virginiamycin and intestinal structure in pigs (van Leeuwen et al., 2002).  Pigs weaned at 21 days 
of age were fed diets containing either 0 or 40 mg/kg of virginiamycin for 32 days, starting at 
seven days post-weaning.  At day 31 post-weaning, pigs were challenged with E. coli.  The 
section observed was mid-jejunum taken 5.5 meters distal from the ligament of Treitz.  Crypt 
depth was significantly decreased and the number of crypt goblet cells was significantly 
increased in the virginiamycin group.  In the second trial, pigs were fed for 14 days starting on 
day fourteen post-weaning.  The virginiamycin-fed pigs had longer villi, but crypt depth was 
unchanged (van Leeuwen et al., 2002). 
 
Impact on Nutrient Transport 
 Few studies have investigated the impact of in-feed antibiotics on nutrient transport in 
pigs.  No reports were found in the literature on virginiamycin and nutrient transport in pigs.  
Walsh and colleagues (2012) recently published a study investigating the antibiotic carbadox in 
newly weaned pigs and nutrient transport before and after a Salmonella challenge.  Carbadox-fed 
piglets had less glucose, phosphorus, and glutamine transport at 7 days post weaning compared 
with control pigs, but transport did not differ at any time post-Salmonella challenge (Walsh et al., 
2012).  Several gut-associated changes occur during weaning so comparability between nutrient 
transport data in weaning piglets and grower pigs may be limited. 
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Thesis objective 
The effects of in-feed antibiotics on growth and feed conversion have been known for 
decades.  However, the mechanisms by which this occurs are not well defined.  In lieu of recent 
debates on the safety of public health in relation to antibiotic-fed animals, it is important to 
understand the mechanisms by which these antibiotics work.  Beneficial effects of in-feed 
antibiotics on energy and nitrogen utilization have been shown in several animal species, 
including swine (Dierick et al., 1986; Vervaeke et al., 1979).  Previous studies on the nutritional 
effect of in-feed antibiotic have focused on digestibility and utilization of protein, energy, and 
phosphorus.  To our knowledge, no study has investigated the effect of virginiamycin on 
intestinal structure and nutrient and ion transport in grower pigs.  Therefore, our study aimed to 
investigate the structural and functional indices of the intestine in grower pigs feed corn-soybean 
diets supplemented with virginiamycin.  We hypothesized that diets with virginiamycin would 
increase intestinal surface area and nutrient processing capacity compared with diets without 
virginiamycin.  The mechanism by which in-feed antibiotics promote growth in pigs is most 
likely multifaceted and intestinal structure and function is an important component in 
determining the true manner of virginiamycin. 
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Table 1.1 Summary of agencies’ conclusions, recommendations, and actions from 1969 to 2012 regarding antibiotic use in food-producing 
animals1   
Year Organization Conclusion Recommendation/Action 
1969 
Joint 
Committee2 
Antimicrobial use in food-producing 
animals poses a hazard to human and 
animal health 
1. Only use antibiotics in animal feed that are not used as 
therapeutic agents in humans or animals 
1970 FDA  
1. Antimicrobial drugs used in human medicine should meet 
certain guidelines to be used for growth promotion 
2. Resulted in code of federal regulations that require 
companies to submit research demonstrating product does 
not promote bacterial drug resistance 
1980 NAS 
Limited epidemiological research 
available on antimicrobials in animal 
feed 
1. Gain evidence to either prove or disprove the safety of 
penicillin and tetracycline use in animals 
1988 IOM 
Unable to find direct evidence that 
penicillin or tetracycline in animal feed 
propose a human health hazard 
1. Further study on antibiotic use in animals and associated 
human health effects 
1997 WHO 
All uses of antimicrobials led to 
selection of resistant bacteria 
 
1. Do not use same drugs used in humans or with known cross-
resistance to antimicrobials used in humans 
2. Develop a systematic approach to replacing antimicrobials 
3. Risk management needed including prudent use of 
antibiotics, education and veterinary approval 
1999 NRC  
1. Establish national databases to support policy development 
for approval and use of antibiotics in animals 
2. FDA establish panel of experts for oversight of development 
and use of antibiotics 
1999 GAO 
Extent to which bacterial resistance, as a 
result of antibiotic use in animals, has 
led to human illness or death cannot be 
estimated at this time 
1. Departments of Agriculture and Health and Human Services 
work together to develop a plan to determine use of 
antibiotics in agriculture 
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Table 1.1 Continued  
Year Organization Conclusion Recommendation/Action 
1999 ECR 
Actions should be taken promptly to 
reduce overall use of antimicrobials 
1. Antimicrobials used prudently 
2. Research new ways to prevent and treat infections 
2003 
FAO/OIE/ 
WHO 
There is accumulating evidence of 
adverse human health effects due to 
resistant bacteria from antimicrobial use 
in animals 
1. WHO appoint a group of experts and develop risk 
assessments 
2. Codex collaborate with OIE for a risk management system 
2003 IOM 
Determined 13 factors that account for 
the emergence of new or enhanced 
microbial threats 
1. FDA ban all antibiotics used for growth promotion that are 
in the same class as antibiotics used in human medicine 
2003 
FDA 
(GFI#152) 
 
1. FDA must determine that a drug is safe and effective for its 
intended use in animals and safe with regard to human health 
2004 
FAO/OIE/ 
WHO 
Good agricultural practices could 
eliminate the need for in-feed antibiotics 
1. Establish a list of antibiotics deemed critically important to 
human health by WHO 
2. Implement resistance surveillance systems 
3. Codex/OIE task force to develop risk management options 
2004 GAO 
Resistant bacteria can be transferred and 
may pose a threat to human health 
1. FDA expedite risk assessments of critically important 
antibiotics to see if use of those antibiotics should be 
prohibited in animals 
2. Secretary of Agriculture and Human and Health Services 
develop a plan for collecting data on antibiotic use in 
animals 
2005 Codex 
Provided guidance for the responsible 
and prudent use of antimicrobials in 
animals 
1. Veterinary prescription for antibiotic use 
2. Do not use antibiotics for growth promotion if cross-
resistance occurs 
2009 AAM 
Resistance is natural phenomenon that 
cannot be eliminated 
1. Find new ways to deal with current resistance 
2. Try to control future resistance by prudent and responsible 
use of antibiotics in animals 
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Table 1.1 Continued 
Year Organization Conclusion Recommendation/Action 
2011 WHO 
Approach a solution to antibiotic 
resistance in a holistic and multifaceted 
manner 
1. Eliminate the use of antibiotics for growth promotion 
2. Require veterinary prescription for antibiotics use and only 
use antibiotics deemed critically important for humans when 
justified 
2012 
FDA 
(GFI#209) 
Antimicrobial resistance in humans is a 
rising concern 
1. Voluntary adoption of limiting use of medically important 
drugs to times when they are necessary for assuring animal 
health 
2. Veterinary oversight or consultation for antimicrobial use 
1Abbreviations: NAS, National Academy of Sciences; IOM, Institute of Medicine; WHO, World Health Organization; NRC, National 
Research Council; GAO, U.S. Government Accountability Office; ECR, European Commission Report; FAO, Food and Agriculture 
Organization; OIE, World Organization for Animal Health; AAM, American Academy of Microbiology  
2The Joint Committee on the Use of Antibiotics in Animal Husbandry and Veterinary Medicine, Her Majesty’s Stationery Office 
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Table 1.2 Mechanisms by which in-feed antibiotics may promote growth in animals 
Mechanism Result 
Shifts in microbiota Decrease in microbial use of nutrients resulting in increased nutrients 
available to the host 
Decrease in pathogenic microbiota 
Decrease in toxic products 
Immunity Lower levels of proinflammatory cytokines 
Reduced influx of inflammatory cells into the mucosa 
Transit time Slower digesta passage rate resulting in increased time for absorption 
Nutrient digestibility Increased digestibility of protein, energy, and minerals 
Intestinal structure Increase in absorptive surface area 
Nutrient transport Increased nutrient uptake via increased surface area or up-regulation of 
nutrient transporters 
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Figure 1.1 Percent improvement in daily gain and feed per unit of gain in 
swine fed in-feed antibiotics over pigs fed diets without antibiotics.  
Antibiotics improve daily gain in pigs by 16.4% during the starter period, 
10.6% during the grower period, and 4.2% during the entire grower-finisher 
period.  Antibiotics improve feed per unit of gain in pigs by 6.9% during the 
starter period, 4.5% during the grower period, and 2.2% during the entire 
grower-finisher period.  Adapted from Cromwell, 2002. 
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Metabolic 
• Increase 
• Water and nitrogen excretion 
• Liver protein synthesis 
• Gut alkaline phosphatase 
• Decrease 
• Fatty acid oxidation 
• Phosphorylation reactions 
• Bile degradation products 
Nutritional 
• Increase 
• Nutrient availability via shifts in 
microbiota 
• Digestibility of nutrients 
• Absorption of nutrients 
Disease-Control 
• Decrease 
• Disease-causing organisms 
• Sub-clinical infections 
Figure 1.2 The three categories of mechanisms by which subtherapeutic levels of antibiotics may promote growth in animals. (Braude & 
Johnson, 1953; 1955; Brody et al., 1954; Butaye et al., 2003; Carlson & Fangman, 2000; Cocito, 1979; Feighner & Daskevicz, 1987; 
Gaskins et al., 2002; Hash et al., 1964; Hays, 1978; Henderickx et al., 1981; Koong et al., 1982; Moser et al., 1980; Webster, 1981; 
Weinberg, 1957) 
26 
 
Chapter 2: Impact of Virginiamycin on the Development of Intestinal Structure and 
Functional Capacity in Growing Pigs 
Introduction 
 Growth promoting effects of antibiotics are well documented in several animal species, 
including swine.  However, the mechanisms behind how these antibiotics enhance growth and 
feed efficiency are not completely understood.  Increasing public concern about antibiotic 
resistance has led to increased political pressure to determine if antibiotic use in animals plays a 
role in antibiotic resistance and potential treatment failure in humans. Understanding the 
mechanisms behind antibiotic growth promoters will aid in determining the relationship between 
in-feed antibiotic use in animals and human health. 
 The proposed mechanisms by which antibiotics promote growth are described in three 
main categories including metabolic, nutritional, and disease control effects (Gaskins et al., 
2002).  Early research mainly focused on how antibiotics suppress the growth of pathogenic 
antibiotics while more recent research has investigated the nutritional effects of antibiotics.  The 
impacts of in-feed antibiotics on shifts in microbial populations, nutrient availability, rate of 
passage, and nutrient digestibility have been investigated.  However, little research has been 
done on the impact of antibiotics on intestinal structure and nutrient transport capacity. 
 Virginiamycin, approved for use in the United States in 1975, is an in-feed antibiotic used 
for swine (FDA, 2004).  Virginiamycin improves average daily gain and feed efficiency in swine 
(Gaines et al., 2005; Gramm et al., 2006; Hays, 1981; Lewis & Giesemann, 1991; Schinckel, 
1993; Zimmerman, 1986).  Research has shown that virginiamycin reduces lactic acid bacteria, 
ammonia production, and volatile fatty acid production (Agudelo et al., 2007; Decuypere et al., 
1973; Hedde et al., 1981; Henderickx et al., 1993; Langlois et al., 1978; van Assche et al., 1975; 
27 
 
Vervaeke et al., 1979).  Virginiamycin also reduces the rate of passage (Fausch, 1981; Hedde et 
al., 1981; Ravindran et al., 1984) and improves ileal digestibility of nutrients in pigs (Agudelo et 
al., 2007; Decuypere et al., 1978; Dierick et al., 1986; Lindemann et al., 2002; Stewart et al., 
2010).  Research has shown impacts of virginiamycin within the gastrointestinal tract, but the 
exact mechanisms behind virginiamycin remain largely unknown. 
 The overall objective of this study was to assess the structural and functional 
developments induced in the intestine by the consumption of virginiamycin in grower pigs and to 
determine how these developments may be mechanistically related to the differences in growth 
observed among treatments.  We examined the hypothesis that feeding grower pigs diets with 
virginiamycin is associated with increased intestinal surface area and nutrient processing 
capacity compared with pigs consuming diets without virginiamycin. 
 
Materials and Methods 
Experimental Design 
All animal procedures were approved by the Illinois Institutional Animal Care and Use 
Committee at the University of Illinois Urbana-Champaign.  These piglets were the first 
generation of pigs housed in clean facilities following a depopulation and extensive cleaning at 
the Swine Research Center at the University of Illinois at Urbana-Champaign.  These piglets 
were given one injection of Excede® (ceftiofur crystalline free acid) after birth, weaned at 3 
weeks of age and raised in a weaning facility consuming a non-medicated swine weaning diet.  
At allocation, littermate barrows with similar body weight (n=72; 23.0±1.3 kg; pigs nine weeks 
of age) were randomized to pens in a grower facility.  Pens were randomized to one of three 
treatment groups: 1) a basal corn-soybean meal diet, 2) the basal diet + 11 mg/kg of 
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virginiamycin, or 3) the basal diet + 27.5 mg/kg of virginiamycin.  Within each pen, pigs were 
further randomized to a time point (7 or 14 days).  The control diet was fed to all pigs during 
their acclimation to the new environment from allocation to experimental day zero (3 to 4 days).  
The experiments were conducted in three replicates (n=24 pigs/replicate, 4 pigs/pen, 2 
pens/treatment/replicate).  Feed was a basal corn-soybean meal swine grower diet (Table 2.1).  
Feed was mixed and divided before adding virginiamycin.  Before the trial began, feed 
medication assays were conducted to ensure proper levels of antibiotic in each feed (0, 11, and 
27.5 mg/kg of virginiamycin).  Virginiamycin at the 11 mg/kg diet level is currently approved 
for use in pigs up to 120 pounds for growth promotion and feed efficiency.  Virginiamycin at the 
27.5 mg/kg diet level is currently approved for use in pigs up to 120 pounds for prevention of 
swine dysentery.  These levels of virginiamycin were chosen, in conjunction with our funding 
agency, to understand the impacts on intestinal function and structure at the level used for 
improved performance and for prevention of disease. 
 
Body Weight and Feed Intake 
Pigs were allowed to consume the feed and water ad libitum.  Pigs were weighed 
individually on allocation day, experimental day zero, and every other day throughout the study 
with final body weight taken on euthanasia day.  Feeders were weighed empty, before adding 
feed, and every other day to record feed consumption of each pen.  Feed bags were weighed 
before being added to the feeder.  Feed intake and feed per unit of gain were assessed by pen 
because individual assessment was not feasible.  Total feed intake for each pen was divided by 
the number of pigs in the pen and then divided by the number of days to determine average daily 
feed intake per pig.  For each individual pig, final weight was subtracted from day zero weight 
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and divided by days of treatment to determine daily weight gain.  Daily weight gain and feed 
intake was averaged within pens.  Average daily feed intake per pig was divided by average 
daily weight gain to determine feed per unit of gain. 
 
Sample Collection 
After the specified time period (7 or 14 days), a telazol, ketamine, and xylazine 
intramuscular anesthetic was followed by intravenous sodium pentobarbital (Fatal Plus; Vortech 
Pharmaceuticals, Chicago, IL) for euthanasia.  The intestine was quickly removed starting with 
the duodenum excised proximal to the ligament of Treitz and distal of the stomach.  The intestine 
distal to the ligament of Treitz and proximal to the ileocecal valve was removed and divided 
equally in half with the proximal half designated as jejunum and distal half designated as ileum.  
The entire large intestine was removed distal to the ileocecal valve.  Segments were flushed with 
ice-cold saline and weighed.  The length of duodenum was measured by suspending it 
longitudinally with a 10 g weight attached to the distal end while the remaining segments were 
laid out and measured with a measuring tape.  Sample location was consistent among pigs to 
reduce variation due to sampling location.  A 4-cm sample of each intestinal segment was taken 
and placed in oxygenated Kreb’s for electrophysiological analysis.  Two 1-cm samples of each 
segment were immediately snap frozen in liquid nitrogen and stored at -80°C for analysis of 
DNA, RNA, protein, and disaccharidase activity.  A 1-cm section of each segment was scraped 
free of mucosa and placed on separate slides for mucosa and submucosa weight.  An additional 
1-cm section of each segment was opened longitudinally, stapled to a square of cardstock at the 
proximal and distal ends, mucosa side up, and placed in 10% neutral buffered formalin (Sigma-
Aldrich, St. Louis, MO) for histomorphology and immunohistochemistry analysis. 
30 
 
Mucosa and Submucosa Mass 
Mucosal and submucosal mass was determined gravimetrically by desiccating samples on 
glass slides and subtracting the mass of the slide from that of slide plus sample.  Glass slides 
were dried in an oven at 120°C for 10 minutes, cooled in a desiccator with a vacuum for 10 
minutes, and weighed.  Intestinal samples of a specific length were collected as described above.  
Samples sat at room temperature for at least 24 hours and were then dried for one hour in a 
drying oven at 95°C.  Samples were removed from the oven and immediately placed in a 
desiccator for one hour.  Samples were then removed and weighed immediately. 
 
DNA, Protein, RNA Quantification 
Intestinal homogenates for DNA and protein quantification were prepared with 0.25 g 
intestinal tissue into 1 ml of  diethyl pyrocarbonate (DEPC; 2 mL/L; Sigma-Aldrich, St. Louis, 
MO) homogenized (Tissue Tearor, model 23 985370, BioSpec Products Inc., Bartlesville, OK) 
individually for 30 seconds.  After preparing the appropriate dilution, DNA content of the 
intestinal samples was determined using the Hoechst microplate method (Latt & Stetten, 1976).  
Briefly, each well of a black 96-well microplate (Fisher Scientific, Pittsburg, PA) was filled with 
8 µl of intesinal homogenate or prepared herring sperm standard and 200 µl of a buffer solution 
containing 10 mM Tris, 1 mM EDTA, 200 mM NaCl, and 1.6 nmol 33258 bisBenzimide 
Hoechst dye (Sigma B2883) at pH 7.4.  Intestinal DNA concentration was quantified in sample 
homogenate using fluorescence at an excitation of 360 nm, emission of 450 nm (SpectraMax 
Gemini XS  fluorometer, Molecular Devices, Sunnyvale, CA), and standard curve methodology 
with a  Herring sperm DNA standard (PromegaD1811, Madison, WI).   
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Intestinal protein concentration was determined using the BSA method (Pierce 
Biotechnology, Rockford, IL) following the manufacturer’s protocol.  Briefly, each well of a 96-
well plate was filled with 25 μl of each standard or sample replicate and 200 μl of the working 
reagent.  The plate was placed on a plate shaker for 30 seconds and then covered and incubated 
at 37°C for 30 minutes.  The plate was cooled to room temperature and the absorbance was 
measured at 562 nm using a SpectraMax Plus 384 (Molecular Devices LLC., Sunnyvale, CA).  
Protein concentration was calculated from a bovine serum albumin (Sigma) standard curve. 
RNA concentration was determined spectrophotometrically.  RNA was isolated from 
intestinal tissue samples using TRIzol® reagent (Life Technologies, Inc., Gaithersburg, MD), 
according to the manufacturer’s specifications.  An overnight cleaning step was performed by 
adding 10 μL of 3M sodium acetate at pH 5.2 and 250 μL of 100% ethanol to samples, briefly 
vortexing and placing samples in a -20°C freezer.  The following morning, samples were 
centrifuged for 15 minutes and the resulting pellet was washed an additional time with 75% 
ethanol.  Total RNA was quantified with a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific Inc, Waltham, MA) at OD260 absorbance, and purity was assessed by determining the 
OD260/OD280 and OD260/OD230 ratios. 
 
Morphometric Analysis of the Mucosal Architecture 
Intestinal sections were fixed in formalin and then transferred to 50% ethanol.  Samples 
were infiltrated with paraffin wax and sectioned to approximately 5 μm thickness with a 
microtome.  Slides were cleared of paraffin with xylene and then rehydrated with a series of 
ethanol washes (100%, 95%, 80%).  Slides were rinsed in tap water for 4 minutes.  Hematoxylin 
stain was applied for 3 minutes, acid ethanol for 15 seconds, and Scott’s Bluing solution for 4 
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minutes.  Slides were washed with water between each application.  Slides were then dehydrated 
in increasing ethanol baths (80%, 95%, 100%) and Eosin Y (diluted 50% in 95% EtOH) was 
applied for 30 seconds in the middle of the 95% EtOH bath.  Slides were placed in xylene and 
cover slipped.  Sections were visualized with Nanozoomer Slide Scanner Digital Pathology 
System (Hamamatsu, Bridgewater, NJ) and NDP View imaging software.  Villus height, mid-
villus width and crypt depth were measured in 8 to 20 vertically well-orientated villi and crypts 
within each sample.  Villus surface area was calculated for each villus by multiplying villus 
height by villus width. 
 
Epithelial Cell Proliferation 
The immunohistochemical detection of proliferating cell nuclear antigen (PCNA) was 
used as an index of crypt cell proliferation.  Formalin-fixed, paraffin-embedded sections sliced to 
approximately 5 µm thickness were cleared of paraffin with xylene and then rehydrated through 
graded ethanol washes (100%, 95%, 80%, and 70%).  Slides were then rinsed in tap water for 5 
minutes.  Antigen retrieval was performed by placing slides in a 95°C citrate buffer (10mM citric 
acid, 0.05% Tween 20, pH 6.0, Sigma-Alrdich, St. Louis, MO) bath for 5 minutes.  After 5 
minutes, the citrate bath with slides was placed at room temperature for 20 minutes followed by 
two-5 minute washes in room temperature phosphate buffered saline (PBS; 2 mM Na2H2PO4 
H2O, 8.5 mM Na2HPO4, 1.5 mM NaCl, pH 7.4).  Endogenous peroxidase activity was quenched 
with 3% hydrogen peroxide (Fisher Scientific) for 10 minutes followed by two-5 minute washes 
in PBS.  Five percent normal horse serum (NHS) was applied to the slides for 20 minutes to 
block non-specific binding sites and then slides were incubated for 60 minutes with primary 
PCNA antibody (Millipore Billerica, MA) diluted 1:325 in 1% NHS PBS.  A biotinylated 
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universal secondary antibody and ABC complex (Vectastain Elite ABC kit, Vector, Burlingame, 
CA) were prepared and utilized according to manufacturers’ instructions.  Slides were washed 
twice for 5 minutes after each application of the primary and secondary antibodies, and ABC 
complex.  Finally, sections were stained for 3 to 4 minutes with VIP (Peroxidase Substrate Kit, 
Vector), dehydrated in increasing ethanol baths (70-100%), finishing with xylene and cover 
slipped.  Nanozoomer Slide Scanner Digital Pathology System and NDP View imaging software 
were used to capture images at 20x magnification.  PCNA positive cells in 8-10 well-oriented 
crypts of each sample were counted using ImageJ software (National Institutes of Health, 
Bethseda, MD). 
 
Disaccharidase Specific Activity 
Intestinal homogenates were prepared with 0.25 g intestinal tissue into 1 mL of 
homogenation buffer containing protease inhibitors (0.45 mol/L sodium chloride, 0.001 mol/L 
phenylmethylsulfonyfluoride, 0.002 mol/L iodoacetic acid).  After preparing the appropriate 
dilution in homogenation buffer (50 ul homogenate + 50 ul buffer), sucrase and lactase specific 
activities were determined by the method of Dahlquist (Messer & Dahlqvist, 1966).  Briefly, the 
intestinal homogenates were incubated in either lactose or sucrose buffer for 60 minutes at 37°C.  
The hydrolysis of the disaccharide by the action of the disaccharidase in the tissue homogenate 
was stopped by the addition of 2.0% zinc sulfate and 1.8% barium hydroxide.  Following 
centrifugation and transfer of supernatant to a 96-well microplate, the amount of glucose released 
was detected with a glucose oxidase reagent (Thermo Scientific, Middletown, VA) using a 
microplate spectrophotometer (Molecular Devices, Sunnyvale, CA).  Liberated glucose was 
quantified using standard curve methodology after subtracting each sample’s internal control for 
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endogenous glucose.  Disaccharidase activity was normalized to cellular protein content of the 
same homogenate as measured by BCA assay and expressed as the amount of glucose release per 
hour per milligram of protein. 
 
Mucosal Ion and Nutrient Transport 
Modified Ussing chambers (Physiologic Instruments, San Diego, CA) were used for 
electrophysiological analysis of nutrient transport and secretory capacity across intestinal 
segments as previously described (Kles et al., 2001).  Duplicate sections of duodenum, jejunum, 
ileum and colon were stripped of muscularis (outer serosal layer), cut longitudinally along the 
mesentery, and mounted in modified Ussing chambers to expose 0.5 cm
2
 of tissue.  The tissue 
was bathed in 8 mL of oxygenated (95% O2/5% CO2) modified Kreb’s buffer maintained at 37°C 
with a circulating water bath (Fischer Scientific, Itasca, IL).  Dual channel voltage current 
clamps (VCC MC2, Physiologic Insruments Inc.) were utilized to voltage clamp the 
transepithelial potential of the intestinal segments to zero.  Basal transmucosal short-circuit 
current (Isc; uA/cm
2), resistance (R; Ω•cm2), and potential difference (Pd; mV) were measured 
after an equilibration period. 
Active transport was determined by measuring the change in short-circuit current induced 
by the addition of 10 mM glucose, glutamine, or arginine (Sigma-Aldrich, St. Louis, MO) to the 
medium on the mucosal side.  Each addition to the mucosal side was osmotically balanced by the 
addition of 10 mM mannitol (Sigma-Aldrich) to the serosal reservoir.  Neurally mediated 
secretion was measured by the addition of 0.1 mM serotonin and immune mediated secretion 
was measured by the addition of 0.1 mM carbachol (Sigma-Aldrich) to the serosal medium.  
Dual-channel voltage/current clamps (VCC MC2, Physiologic Instruments) with a computer 
35 
 
interface allowed for real time data acquisition and analysis (Acquire & Analyze software, 
Physiologic Instruments). 
 
Statistical Analysis 
Analysis of variance was used to statistically analyze the data using the Mixed Model 
fitted with a split plot design.  Treatment (0, 11, 27.5 mg/kg of virginiamycin) was included in 
the whole plot, whereas time (7 or 14 days) was included in the subplot.  Treatment, time, and 
the interaction between treatment and time were the main fixed effects.  Replicate, the interaction 
between replicate and treatment, and pen nested within treatment were included as the random 
effects.  Preplanned contrasts between virginiamycin and control groups were completed. When 
specific intestinal segment data were analyzed, each respective segment was analyzed separately 
from one another (i.e. duodenal values were not compared with jejunal values).  All data were 
checked for normality by the Shapiro-Wilk statistic.  A log 10, square root, or reciprocal 
transformation was applied to all non-normal data.  After p-values were obtained, data were re-
transformed to acquire the correct mean estimate and the standard error of retransformed data are 
presented as an average of standard error (SE) values calculated from both the upper and lower 
retransformed confidence intervals of group means.  If the main effect of time, treatment, or the 
interaction between time and treatment was significant, means were separated using the least 
significant difference and considered significant at p≤0.05. 
Principal component analyses (PCA) were completed on data derived from the control 
and 11 mg/kg virginiamycin groups at day seven (PCA 1; n=23 piglets; 77 variables) and day 
fourteen (PCA 2; n=24 piglets; 73 variables) as outlined by Jolliffe (2002).  Data were not 
included from the 27.5 mg/kg virginiamycin group because this level of virginiamycin is not 
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FDA approved for use for growth promotion and feed efficiency.  Our primary objective was to 
obtain an overview of changes in structure and function along the intestinal tract with 
virginiamycin used for growth promotion and feed efficiency.  In both initial PCAs, seventy-five 
percent of the total variance was accounted for by ten factors; therefore, we retained ten factors 
in the final analyses.  Variables that did not load on any factor retained (correlation coefficient 
between variables and factors │r│≤ 0.5) were excluded from the final analyses.  When several 
variables were significantly correlated (│r│> 0.6, p<0.05) within a group of similar variables, 
only the variables with the highest factor loadings were kept for the final analyses.  T-tests were 
conducted on rotated component scores to detect if the principal components discriminated 
between treatment groups.  Statistical analyses were performed using SAS (Version 9.3; SAS 
Institute, Cary, North Carolina). 
 
Results 
 A total of 71 pigs completed this study.  The one pig not included in the final analysis 
was eliminated from the study due to illness.  Weights from three pens at day seven were not 
included in final analysis due to equipment malfunction resulting in inaccurate weights for those 
pigs. 
 
Dietary Intake and Pig Growth 
Body weight did not differ among groups at allocation or experimental day zero.  Main 
effect treatment differences were not observed for feed efficiency or feed intake.  Average daily 
gain tended to be higher in the 11 mg/kg virginiamycin group compared with control at day 
seven (p=0.056; Table 2.2).  Final body weight (7d pooled=31.2±1.1, 14d pooled=36.6±1.0 kg, 
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p<0.00005), daily feed intake (7d pooled=1.46±0.07, 14d pooled=1.73±0.07 kg, p<0.00005), and 
feed per unit of gain (7d pooled=1.86±0.13, 14d pooled=2.09±0.12 kg/kg, p=0.015) were higher 
at day fourteen day compared with day seven (Table 2.2).   
 
Gross Intestinal Morphology 
Gross intestinal structure was assessed by intestinal weight, length, mucosal and 
submucosal mass.  Duodenal length per body weight (7d pooled=1.26±0.07, 14d 
pooled=1.15±0.07 cm/kg) and weight per body weight (7d pooled=1.39±0.08, 14d 
pooled=1.26±0.08 g/kg) were less at day fourteen compared with day seven (p=0.032, p=0.041, 
respectively; Table 2.3).  Duodenal mucosal mass increased over time in the control pigs, but it 
did not in pigs fed diets supplemented with virginiamycin which resulted in less duodenal 
mucosa in the 11 mg/kg virginiamycin group at day fourteen compared with control (p=0.038; 
Table 2.4; Figure 2.1).  Submucosal mass tended to be less in the duodenum with virginiamycin 
treatment at day fourteen compared with control (p=0.066; Table 2.4). 
Jejunal length per body weight decreased over time (7d pooled=22.4±0.89, 14d 
pooled=18.8±0.88 cm/kg, p<0.00005; Table 2.3).  Virginiamycin supplemented at 11 mg/kg diet 
tended to increase jejunal mass at seven days compared with control (p=0.069; Table 2.3).  
Submucosal mass decreased over time in the jejunum (7d pooled=0.173±0.021, 14d 
pooled=0.142±0.021 g/cm, p=0.014; Table 2.4).  Virginiamycin increased jejunal submucosal 
mass compared with control when virginiamycin treatment groups were contrasted with control 
(p=0.037; Table 2.4; Figure 2.2).   
 Ileal length per body weight (7d pooled=22.4±0.89, 14d pooled=18.8±0.88 cm/kg) and 
weight per body weight (7d pooled=33.5±0.87, 14d pooled=29.1±0.86 g/kg) were less at day 
38 
 
fourteen compared with day seven (p<0.00005, p=0.0002, respectively; Table 2.3).  Mucosal 
mass (7d pooled=0.292±0.022, 14d pooled=0.356±0.022 g/cm) and submucosal mass (7d 
pooled=0.197±0.018, 14d pooled=0.229±0.018 g/cm) increased over time in the ileum (p=0.002, 
p=0.028, respectively; Table 2.4). 
Colon length per body weight (7d pooled=9.65±0.26, 14d pooled=8.03±0.25 cm/kg) and 
weight per body weight (7d pooled=45.2±1.2, 14d pooled=41.3±1.2 g/kg) were less at day 
fourteen compared with day seven (p<0.00005, p=0.005, respectively; Table 2.3).  However, 
mucosal mass increased over time in the colon (7d pooled=0.398±0.044, 14d 
pooled=0.464±0.051 g/cm, p=0.019; Table 2.4). 
 
Histomorphology 
Crypt-villus architecture (villus height, mid-villus width, and crypt depth) was measured 
by histomorphology to assess the effects of virginiamycin on epithelial architecture.  
Virginiamycin treatment increased villus surface area in the duodenum compared with control 
when virginiamycin treatment groups were contrasted with control (p=0.048; Table 2.5; Figure 
2.3).  Villus surface area in the duodenum increased with time (7d pooled=78,280±3544, 14d 
pooled=92,196±3491 µ
2
, p=0.003) and involved increases in villus height (7d pooled=377±12.6, 
14d pooled=416±12.4 µ, p=0.016) and width (7d pooled=205±5.0, 14d pooled=221±4.9 µ, 
p=0.009; Table 2.5).  Pigs fed the diet containing 27.5 mg/kg of virginiamycin had shallower 
crypts in the jejunum at day fourteen compared with day seven (p=0.023; Table 2.5; Figure 2.4).  
Ileal villus surface area tended to increase with time (7d pooled=61,247±2654, 14d 
pooled=66,537±2716 µ
2
, p=0.080; Table 2.5).  Colonic crypts were deeper in virginiamycin fed 
pigs when the 11 mg/kg virginiamycin group was contrasted with control (p=0.044; Table 2.5; 
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Figure 2.5).  Colonic crypts were deeper at fourteen days compared with seven days (7d 
pooled=451±19, 14d pooled=481±19 µ, p=0.013; Table 2.5). 
 
Epithelial Cell Proliferation 
Epithelial cell proliferation, measured by immunohistochemistry for PCNA-positive 
cells, was assessed in pigs fed diets containing 0 mg/kg and 11 mg/kg of virginiamycin for seven 
days.  Pigs consuming the diet containing 11 mg/kg of virginiamycin had more PCNA-positive 
cells per ileum crypt than control pigs (p=0.003; Figure 2.6) with a similar trend in the 
duodenum (duodenum, p=0.055; Table 2.6). 
 
DNA, RNA, and Protein Concentration 
The effects of virginiamycin at the cellular level of intestinal tissue were assessed 
through quantification of intestinal DNA, RNA, and protein concentration.  Intestinal DNA, 
RNA, and protein concentration were not impacted by virginiamycin treatment (Tables 2.7-2.9).  
Cellular RNA concentration tended to be lower at fourteen days compared with seven days in the 
proximal small intestine (duodenum, 7d pooled=3.93±0.78, 14d pooled=3.07±0.78, p=0.061; 
jejunum, 7d pooled=0.349±0.013, 14d pooled=0.327±0.016 mg RNA/mg DNA, p=0.083; Table 
2.7).  DNA concentration was greater at fourteen days compared with seven days in the 
duodenum (7d pooled=1.20±0.13, 14d pooled=1.55±0.13 mg/mg tissue, p=0.011; Table 2.9). 
 
Intestinal Disaccharidase Activity 
Sucrase activity in the duodenum of pigs fed diets containing 11mg/kg of virginiamycin 
was lower at day seven compared with control but increased over time in the virginiamycin 
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treatment groups resulting in no differences among groups at day fourteen (p=0.039; Table 2.10; 
Figure 2.7).  Lactase activity tended to increase over time with virginiamycin treatment in the 
duodenum resulting in a trend towards increased lactase activity with virginiamycin treatment 
compared with control at day fourteen (p=0.086, Table 2.10).  Sucrase activity was lower at day 
fourteen compared with day seven in the ileum (7d pooled=88.6±27, 14d pooled=70.1±22 U/g 
protein, p=0.041; Table 2.10).  
 
Mucosal Ion and Nutrient Transport 
Mucosal resistance, a measure of passive ion transport, was not impacted by 
virginiamycin treatment.  Potential difference, a measure of total ion transport, tended to be 
lower in the duodenum with virginiamycin when values from pigs fed the diet containing 11 
mg/kg of virginiamycin were contrasted with control (p=0.095; Table 2.11).  Mucosal resistance 
(7d pooled=103±10, 14d pooled=127±13 Ω∙cm2) and potential difference (7d pooled=1.57±0.40, 
14d pooled=2.80±0.62 mV) increased over time in the jejunum (p=0.033, p=0.035, respectively; 
Table 2.11).  Potential difference tended to increase over time in the ileum (7d pooled=1.11±1.1, 
14d pooled=1.99±1.1 mV, p=0.066; Table 2.11).  Ileal potential difference tended to be higher 
with virginiamycin treatment when the values from pigs fed the diet containing 11 mg/kg of 
virginiamycin were contrasted with control (p=0.094; Table 2.11).  Potential difference was 
increased in the colon of pigs fed the diet containing 27.5 mg/kg of virginiamycin compared with 
control (p=0.048; Table 2.11; Figure 2.8).  Basal short-circuit current, a measure of active ion 
transport, tended to be greater in the colon with virginiamycin treatment when values from 
virginiamycin fed pigs were contrasted with control (p=0.056; Table 2.11). 
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Sodium-coupled glucose transport was increased with virginiamycin treatment in the 
duodenum when virginiamycin treatments groups were contrasted with control (p=0.025; Table 
2.12; Figure 2.9).  Virginiamycin tended to increase glutamine transport in the duodenum when 
the 11 mg/kg virginiamycin group was contrasted with control (p=0.083; Table 2.12).  Duodenal 
glutamine transport was lower at day fourteen compared with day seven (7d pooled=3.12±0.71, 
14d pooled=1.63±0.69 µA/cm
2
, p=0.007; Table 2.12).  Virginiamycin increased glucose 
transport in the jejunum when virginiamycin treatments were contrasted with control (p=0.045; 
Table 2.12; Figure 2.10).  Jejunal glucose transport was greater at day fourteen compared with 
day seven (7d pooled=2.33±1.6, 14d pooled=4.68±1.9 µA/cm
2
, p=0.028; Table 2.12).  
Virginiamycin treatment increased electrogenic glutamine transport in the jejunum compared 
with control (p=0.010; Table 2.12; Figure 2.11).  Jejunal glutamine transport tended to decrease 
over time (7d pooled=2.99±0.65, 14d pooled=2.00±0.44 µA/cm
2
, p=0.088; Table 2.12).  
Virginiamycin supplemented at 11 mg/kg diet increased arginine transport in the jejunum 
compared with control (p=0.046; Table 2.12; Figure 2.12).  Pigs consuming diets supplemented 
with virginiamycin had less ileal arginine transport compared with pigs consuming the control 
diet at day seven; however by day fourteen, pigs consuming the diet supplemented with 11 
mg/kg of virginiamycin had greater ileal arginine transport compared with control (p=0.042; 
Table 2.12; Figure 2.13). 
Serotonin induced chloride secretion tended to increase over time in the duodenum (7d 
pooled=0.614±0.40, 14d pooled=0.863±0.44 µA/cm
2
, p=0.087; Table 2.13).  Serotonin induced 
chloride secretion was decreased in the 27 mg/kg virginiamycin group compared with the 11 
mg/kg group in the jejunum (p=0.028; Table 2.13).  However, it tended to be higher in the 11 
mg/kg virginiamycin group compared with control when the 11 mg/kg virginiamycin group was 
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contrasted with control (p=0.060; Table 2.13).  Carbachol induced chloride (CCH) secretion 
decreased over time in the jejunum (7d pooled=24.6±11, 14d pooled=13.0±6.0 µA/cm
2
, p=0.033; 
Table 2.13).  Ileal carbachol induced chloride secretion decreased in control pigs, but it increased 
in pigs fed the diet supplemented with 11 mg/kg of virginiamycin over time resulting in 
increased carbachol induced chloride secretion in the 11 mg/kg virginiamycin group at day 
fourteen compared with control (p=0.017; Table 2.13; Figure 2.14). 
 
Principal Component Analysis 
PCA 1 
PCA of data from day seven was optimized by removing from the analysis the variables 
that did not load on any factor retained.  Variables that did not load on the retained factors 
include: mass of the small intestine (SI), mucosal mass of the duodenum, jejunum, and ileum, 
ileal submucosal mass, duodenal and jejunal villus height, duodenal crypt depth, protein 
concentration in the duodenum, jejunum, and colon, duodenal DNA, jejunal RNA, duodenal 
short circuit current (Isc), glucose, glutamine, and arginine transport, jejunal glucose transport, 
jejunal sucrase and lactase activities, ileal resistance, Isc, potential difference, and CCH, colonic 
sucrase activity, colonic resistance and glucose transport, and duodenal epithelial cell 
proliferation (PCNA). 
Redundant variables were also removed as described earlier.  For example, feed per unit 
of gain and average daily gain were highly correlated (r -.88) and average daily gain was used 
for the final analysis.  Similarly, significant correlations were observed between: colonic 
mucosal and submucosal mass (r 0.63); RNA and DNA within the ileum and colon (r -0.91 and r 
-0.74, respectively); duodenal glutamine transport and serotonin-induced chloride secretion 
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(5HT); jejunal Isc and potential difference (r 0.98); jejunal glutamine transport with arginine 
transport (r 0.82), 5HT (r 0.89), and CCH (r 0.72); ileal glucose transport and 5HT with  
glutamine transport (r 0.92; r 0.68, respectively) and arginine transport (r 0.85; r 0.71, 
respectively); colonic arginine transport, 5HT and CCH (r >0.77). 
The final analysis included twenty-three pigs and thirty-seven variables (Table 2.14).  
Eighty-four percent of the variance among pigs was accounted for by the ten retained factors.  
The first seven factors are shown in Table 2.14.  Factor 1 explained 17.8% of total variance.  The 
variables with the highest loadings on factor 1 were: duodenal resistance, colonic arginine 
transport, ileal 5HT and glucose transport, and jejunal DNA and resistance.  Factor 2 explained 
14.1% of the total variance.  Factor 2 was associated with length of small intestine and colon, 
average daily gain, duodenal RNA and glutamine transport, and submucosal mass of duodenum 
and jejunum.  Factor 3 explained 12.3% of the total variance.  Factor 3 was associated with ileal 
PCNA and crypt depth, colonic DNA, mass, and glutamine transport, jejunal crypt depth, 
average daily gain, and duodenal submucosal mass.  Factor 4 explained 9.6% of the total 
variance and was associated with potential difference in the duodenum and colon, jejunal sucrase 
activity, PCNA, and crypt depth, and submucosal mass in the duodenum.  Factor 5 explained 
7.6% of the total variance and was associated with colonic crypt depth and PCNA, jejunal Isc, 
crypt depth, and resistance, and ileal villus height and crypt depth.  Factor 6 explained 6.3% of 
the total variance and was associated with duodenal lactase activity, sucrase activity, and 
glutamine, lactase activity in the jejunum, and colonic Isc and submucosal mass.  The remaining 
retained factors each explained less than 6% of the total variance.   
Proximal gut mucosal resistance and distal gut nutrient transport account for the greatest 
percent of the total variance compared with all other factors at day seven.  The second and third 
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factors are mainly associated with structural components of the gut.  Virginiamycin impacted 
functional indices to a greater extent than structural components which is reflected in this 
principal component analysis. 
 
PCA 2 
PCA of data from day fourteen was optimized by removing from the analysis the 
variables that did not load on any factor retained.  Variables that did not load on the retained 
factors include: mucosal and submucosal mass in the jejunum and colon, duodenal and jejunal 
villus height, colonic crypt depth, duodenal and ileal protein concentration, RNA, and DNA, 
jejunal RNA and DNA, colonic protein concentration and DNA, duodenal sucrase activity, 
duodenal and jejunal potential difference and CCH, ileal glucose transport, and colonic 
resistance and CCH.  
Redundant variables were removed as described previously.  Significant correlations 
were observed between: feed per unit of gain and average daily gain (r -0.84); length of the small 
intestine and colon (r 0.62); mucosal and submucosal mass within the duodenum and ileum (r 
0.70 and r 0.68, respectively); duodenal arginine transport and 5HT (r 0.69); within the jejunum, 
5HT was correlated with Isc (r 0.72), glucose transport (r 0.75), and glutamine transport (r 0.74); 
within the ileum, resistance was negatively correlated with glutamine (r -0.64) and 5HT (r -0.62) 
while 5HT was positively correlated with Isc (r 0.70), arginine transport (r 0.81), and CCH (r 
0.86); colonic sucrase and lactase activities (r 0.79); colonic Isc and potential difference (r 0.90).   
The final analysis included twenty-four pigs and thirty-four variables (Table 2.15).  
Eighty-five percent of the variance among pigs was accounted for by the ten factors retained.  
The first seven factors are shown in Table 2.15.  Factor 1 explained 16.6% of the total variance.  
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The variables with the highest loadings were: ileal crypt depth, potential difference, and sucrase 
and lactase activities, duodenal and jejunal arginine transport, and jejunal protein concentration.  
Factor 2 explained 12.2% of the total variance.  Factor 2 was associated with crypt depth in 
duodenum and jejunum, glucose transport in duodenum and colon, duodenal lactase activity, and 
jejunual 5HT.  Factor 3 explained 10.6% of the total variance.  Factor 3 was associated with 
duodenal submucosal mass, arginine and glutamine transport in colon, and jejunal resistance.  
Factor 4 explained 9.8% of the total variance and was associated with SI mass, feed per unit of 
gain, and SI length.  Factor 5 explained 7.9% of the total variance and discriminated between 
control and 11 mg/kg virginiamycin groups (p=0.015).  Factor 5 was associated with colonic 
potential difference, jejunal lactase and sucrase activities and resistance, and duodenal lactase 
activity.  Factor 6 explained 7.2% of the total variance and was associated with mass of the 
colon, duodenal resistance, glucose transport, and Isc, and jejunal resistance and sucrase activity.  
Factor 7 explained 6.5% of the total variance and discriminated between control and 11 mg/kg 
virginiamycin groups (p=0.050).  Factor 7 was associated with CCH, resistance, submucosal 
mass, and villus height in the ileum and glucose transport in the colon.  The remaining factors 
each explained less than 6% of the total variance. 
Small intestine functional indices account for the greatest percent of total variance 
compared with all other factors at day fourteen.  Proximal gut disaccharidase activity and distal 
gut ion and nutrient transport dominate the factors that discriminate between control and 
virginiamycin fed pigs.  These variables are indicative of intestinal alteration differences 
between groups and further support the treatment effects observed for increased intestinal 
functional capacity in virginiamycin fed pigs. 
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Discussion 
Feed accounts for approximately two-thirds of the cost of producing market-weight swine 
(Ewan, 2001).  Around 75 to 85% of the total feed used per unit of pork marketed is consumed 
during the growing-finisher period (Cline & Richert, 2001).  An improvement in feed efficiency 
would result in less total feed used and cost-savings for a swine production farm.  In addition, 
higher daily gains would indicate a quicker time to market weight, less time per pig on the farm, 
and lower costs associated with housing and care.  Over 86% of grower-finisher pigs in the 
United States receive in-feed antibiotics (USDA, 2007).  The net economic benefit of using 
antimicrobials in pig production has been estimated to be $2.64 to $3.93 per market hog 
(Zimmerman, 1986; Cromwell, 1999).  Market hog inventory in the United States as of 
December 2012 was 60.5 million head (NASS, 2012).  Miller and colleagues (2003) analyzed 
swine data from the National Animal Health Monitoring System and estimated an improvement 
of 9% in net profits with the use of antibiotics in pigs for growth promotion and feed efficiency 
in the United States. 
The primary outcome of this research was the impact of virginiamycin on intestinal 
structure and function, but the improvements in growth and feed efficiency observed in this 
study are comparable to what is reported in the literature.  A review by Hays (1981) stated that 
virginiamycin improved average daily gain by 10.7% and feed per unit of gain by 6.6% in 
grower pigs.  In our study, virginiamycin supplemented at 11 mg/kg improved daily weight gain 
by 12.2% and feed per unit of gain by 12.9% and virginiamycin supplemented at 27.5 mg/kg 
improved daily weight gain by 8.0% and feed per unit of gain by 12.1%.   Increases in weight 
gain and feed conversion of this magnitude can have substantial financial benefits for producers 
and consumers and greatly impact the amount of pork produced each year. 
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The use of sub-therapeutic levels of antibiotics in food-producing animals has been under 
increasing scrutiny due to concerns of antibiotic resistance.  These concerns resulted in a ban of 
antibiotic use for growth promotion in the European Union.  Impacts of the ban on pig 
production and economic effects are beginning to be reported in the literature.  Aarestrup and 
colleagues (2010) analyzed productivity data before and after the ban, from 1992 to 2008.  They 
showed a steady increase in the number of pigs per sow per year over the entire study period.  
Average daily gain actually increased after the ban; however, the increase in finisher pigs was 
greater prior to the ban.  Total antibiotic was highest in 1992, decreased to half that amount in 
1998, and remained fairly stable at the level until 2008.  No effect on mortality rate was observed 
for weaned pigs (Aarestrup et al., 2010).  The effects of antibiotic growth promoters are well 
documented, but improvements in performance are observed after the ban indicating that growth 
promotion is being supported by other factors.  Understanding the mechanisms behind how 
antibiotics improve performance will aid in determining those factors and provide insight into 
the safety of continued use of antibiotic growth promoters. 
We hypothesized that pigs fed diets supplemented with virginiamycin would have 
increased intestinal surface area compared with pigs fed diets without virginiamycin.  
Interestingly, few significant changes in absorptive surface area were observed among treatment 
groups.  Others have failed to show increased absorptive surface area in the small intestine of 
weaned piglets fed antibiotics (Bosi et al., 2011; Shen et al., 2009).  Van Leeuwen and 
colleagues (2002) observed mixed effects on jejunal surface area of weaned pigs fed 
virginiamycin supplemented diets.  Miles and colleagues (2006) actually observed a decrease in 
ileal surface area of broilers fed virginiamycin.  Our results indicate that increased absorptive 
surface area is not likely a major mechanism by which virginiamycin promotes growth.  
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Recently, a mechanism was proposed by which antibiotics promote growth via reduced 
immunologic stress on the animal (Niewold, 2007).  In our study, virginiamycin appeared to 
protect against an increase in thickness of the mucosa and submucosa in the duodenum over 
time.  Additionally, carbachol induced chloride secretion, used as a measure of immune mediated 
secretion, was increased with virginiamycin in the ileum by day fourteen.  These structural and 
functional changes may support the proposed mechanism by which antibiotics protect the 
intestine against microbial insult and the subsequent infiltration of immune cells into the 
intestinal mucosa (Niewold, 2007).  We did observe an increase in submucosa in the jejunum but 
submucosa is the supporting layer of connective tissue directly under the mucosa and less likely 
directly involved in the immune response.  These aspects are only a portion of the immune 
response mechanism and future studies should investigate immune response parameters, such as 
pro-inflammatory cytokines, to fully elucidate this mechanism. 
Increased digestibility combined with increased growth rate indicates that intestinal 
functional capacity is greater in pigs fed antibiotics.  Virginiamycin has been shown to increase 
absorption of glucose and arginine in mice (Madge, 1969) and improve digestibility of amino 
acids and minerals in the small intestine of pigs (Decuypere et al., 1978; Dierick et al., 1981; 
Dierick et al., 1986; Ravindran et al., 1984; Stewart et al., 2010).  In our study, proximal gut 
nutrient transport was increased by around 2 fold with virginiamycin treatment without an 
increase in cellular protein abundance.  An increase in the number of cells is not responsible for 
the increase in nutrient transport.  This indicates that virginiamycin is not working by creating 
more mature cells but by enhancing the functional capacity of each, already existing cell.  The 
concentration of virginiamycin would be highest in the proximal gut and that is reflected in the 
direct impact on structure and functional capacity in the proximal gut. 
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A unique functional response occurred in the ileum.  Increased ileal arginine transport 
was delayed until day fourteen.  Arginine transport may be lower in the ileum at seven days 
because of increased absorption in the jejunum and, therefore, the nutrients are not reaching the 
distal small intestine.  Additionally, the cells may be rapidly proliferating, immature cells that 
develop into more mature, functional cells by day fourteen.  Virginiamycin has been shown to 
inhibit amino acid breakdown via bacteria in the small intestine (Dierick et al., 1986).  This may 
result in a secondary effect where more amino acids are available in the ileum for transport by 
day fourteen.  This would support the nutrient sparing effect as a proposed mechanism by which 
antibiotics promote growth.  The nutrient sparing effect is thought to be due to an increase in the 
amount of nutrients available to the host due to a reduction in nutrient use by bacteria and, 
therefore, increased absorption.  This direct connection would be true if absorption is based on a 
concentration gradient.  Nutrient concentrations are held constant within the Ussing chambers.  
Increased nutrient transport observed within the Ussing chambers, without increased absorptive 
surface area, indicate the intestinal tissue has the capability of absorbing more nutrients given the 
same concentrations. 
In this study, pigs fed virginiamycin supplemented diets had greater nutrient transport 
capacity in the small intestine without increases in absorptive surface area beyond the duodenum.  
Dierick and colleagues (1981; 1986) suggest that virginiamycin may enhance the activity of 
alkaline phosphatase, Na
+
-K
+
 adenosine triphosphatase, and amino peptidases which are all 
enzymes associated with nutrient absorption.  Given the age and diet of grower pigs, maltase 
activity may provide better insight into discaccharidase activity.  Increases in nutrient transport 
without increases in structural indices may also indicate up-regulation of nutrient transporters or 
enzymes associated with digestion and absorption.  Additionally, virginiamycin increases digesta 
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passage rate which indicates more time for digestion and absorption.  More nutrients available to 
the pig plus an increase in nutrient transport plus increased time for digestion and absorption 
may be partly responsible for the increase in pig performance associated with antibiotics. 
Principal component analysis was completed to provide an overview of the effects of 
virginiamycin along the intestinal tract and to derive a smaller set of variables that account for 
most of the variance to identify a limited number of variables that might indicate mechanisms of 
virginiamycin.  The second PCA identified two factors (factors 5 and 7) that discriminate 
between control and virginiamycin fed pigs.  The factor scores for control were negative which 
indicates that variables negatively correlated with either factor 5 or 7 are associated with control 
pigs and may be decreased in control pigs compared with virginiamycin-fed pigs.  The factor 
scores for the 11 mg/kg virginiamycin were positive which indicates that variables positively 
correlated with either factor 5 or 7 are associated with virginiamycin-fed pigs and may be 
increased in virginiamycin-fed pigs compared with control.  Variables associated with control 
pigs were confined to the ileum, indicating a decrease in absorptive surface area and a decrease 
in resistance indicating increased intestinal permeability.  Variables associated with 
virginiamycin-fed pigs involved increases in functional capacity along the entire intestinal tract 
(Table 2.16).  Although differences in all of these variables were not statistically significant, this 
may indicate more subtle differences, that, when applied over the entire intestinal tract can have 
an impact on growth and feed efficiency. 
One limitation to our study was inherently adopted by the study design.  Split plot design 
takes precision away from the main plot to increase precision in the subplot.  Virginiamycin 
treatment effects were our primary interest but treatment had to be the whole plot.  Due to 
limitations in space, pigs were unable to be housed individually and, therefore, dietary treatment 
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had to be assigned on a pen basis.  It was not feasible to feed different diets within the same pen.  
Another limitation to our study was that it was conducted in a relatively clean facility.  Research 
has shown that growth responses are greater when hygiene is poor (Visek, 1978) and that growth 
responses are two to three times greater on commercial farms than university settings 
(Zimmerman, 1986).  This may help explain our lack of statistically significant differences in 
growth response and feed efficiency. 
The mechanism behind antibiotic growth promoters is likely multifaceted.  With concerns 
of antibiotic use in animals resulting in adverse human health effects, it is important to 
understand the mechanism by which antibiotics promote growth.  Our study demonstrated that 
virginiamycin impacted functional capacity to a greater extent than structural indices (Figure 
2.15).  Virginiamycin directly impacted proximal gut nutrient transport with a more delayed 
response in the distal gut by both increasing nutrient transport and secretion over time and 
providing protection against loss in nutrient transport and secretory capacity.  Increasing our 
knowledge on the mechanisms of antibiotic growth promotion will help to better understand the 
safety of in-feed antibiotics and direct government policy on antibiotic use in animals 
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Table 2.1 Nutrient composition of diets (g/kg) 
 Virginiamycin (mg/kg) 
Ingredient 0 11 27.5 
Ground corn 694.6 694.6 694.6 
Soybean meal 272.1 272.1 272.1 
White grease 10.0 10.0 10.0 
Lime 9.60 9.60 9.60 
Dicalcium phosphate 9.20 9.20 9.20 
Trace mineral mix1 3.50 3.50 3.50 
Vitamin mix2 1.00 1.00 1.00 
Virginiamycin premix3 - 0.10 0.25 
1The premix supplied the following per kilogram of diet: 125 mg Fe (iron sulfate), 
100 mg Zn (zinc oxide), 60 mg Mn (manganese sulfate), 10 mg Cu (copper sulfate), 
1.26 mg I (potassium iodate), 0.3 mg Se (sodium selenite) 
2The premix supplied the following per kilogram of diet: 11,128 IU vitamin A, 2,204 
IU vitamin D3, 66 IU vitamin E, 44 mg niacin, 23.5 mg D-pantothenic acid, 6.58 mg 
riboflavin, 1.58 mg folic acid, 1.42 mg vitamin K, 0.44 mg biotin, 0.24 mg 
pyridoxine, 0.24 mg thiamin, 0.03 mg vitamin B12 
3Contained 110 g of virginiamycin activity per kilogram (V-MaxTM50, Phibro Animal 
Health, Ridgefield Park, NJ) 
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Table 2.2 Body weight, feed intake, feed efficiency, and daily weight gain1-2 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Allocation  
Body Weight 
   
0.356 0.445 0.280 0.226 0.256 0.208 
        7d 23.3 ± 1.3 22.4 ± 1.3 23.3 ± 1.3  
        14d 23.4 ± 1.3 23.1 ± 1.3 22.3 ± 1.3 
Day 0 
Body Weight 
   
0.343 0.390 0.188 0.248 0.231 0.210 
        7d 25.6 ± 1.1 24.1 ± 1.1 25.4 ± 1.1  
        14d 25.5 ± 1.1 25.2 ± 1.1 23.8 ± 1.1 
Final  
Body Weight 
   
0.490 <0.00005 0.244 0.428 0.460 0.435 
        7d 30.8 ± 1.4 30.7 ± 1.7 31.9 ± 1.6  
        14d 37.3 ± 1.4 36.8 ± 1.4 35.8 ± 1.4 
Daily Gain    0.303 0.336 0.056 0.176 0.262 0.184 
        7d 0.758 ± 0.09 0.960 ± 0.10 0.857 ± 0.09  
        14d 0.834 ± 0.09 0.827 ± 0.09 0.864 ± 0.09 
Daily Feed Intake    0.345 <0.00005 0.184 0.245 0.239 0.212 
        7d 1.50 ± 0.10 1.45 ± 0.10 1.44 ± 0.10  
        14d 1.82 ± 0.10 1.68 ± 0.10 1.68 ± 0.10 
Feed per Unit of Gain  
(kg/kg body weight) 
   
0.217 0.015 0.114 0.139 0.150 0.117 
        7d 2.13 ± 0.18 1.64 ± 0.20 1.81 ± 0.19  
        14d 2.17 ± 0.19 2.11 ± 0.18 1.98 ± 0.18 
1Data are expressed as mean ± SEM 
2Unit of measure for weight and feed intake is kilograms 
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Table 2.3 Intestinal weight and length1 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Intestinal 
Weight2 
  
   Duodenum    0.351 0.041 0.481 0.221 0.378 0.265 
        7d 1.35 ± 0.11 1.46 ± 0.11 1.38 ± 0.11  
        14d 1.23 ± 0.11 1.30 ± 0.11 1.27 ± 0.11 
   Jejunum    0.193 0.164 0.069 0.101 0.250 0.131 
        7d 23.8 ± 1.4 28.7 ± 1.5 27.1 ± 1.4  
        14d 25.7 ± 1.4 26.1 ± 1.4 24.8 ± 1.4 
   Ileum    0.210 0.0002 0.227 0.179 0.355 0.361 
        7d 32.2 ± 1.5 35.6 ± 1.6 32.8 ± 1.5  
        14d 29.8 ± 1.5 29.7 ± 1.5 27.9 ± 1.5 
   Colon    0.465 0.005 0.476 0.388 0.376 0.365 
        7d 44.4 ± 2.1 45.5 ± 2.2 45.8 ± 2.1  
        14d 41.1 ± 2.1 41.4 ± 2.1 41.4 ± 2.2 
     
Intestinal 
Length3 
  
   Duodenum    0.498 0.032 0.329 0.472 0.492 0.479 
        7d 1.27 ± 0.12 1.28 ± 0.12 1.22 ± 0.12  
        14d 1.12 ± 0.12 1.13 ± 0.12 1.18 ± 0.12 
   Jejunum/Ileum    0.431 0.00005 0.436 0.430 0.372 0.465 
        7d 22.6 ± 1.3 22.8 ± 1.4 21.7 ± 1.3  
        14d 18.7 ± 1.3 19.1 ± 1.3 18.5 ± 1.3 
   Colon    0.416 0.00005 0.446  0.398 0.378 0.488 
        7d 9.68 ± 0.45 9.87 ± 0.45 9.39 ± 0.43  
        14d 8.01 ± 0.43 8.11 ± 0.43 7.96 ± 0.43 
1Data are expressed as mean ± SEM  
2Unit of measure is grams per kilogram of body weight 
3Unit of measure is centimeters per kilogram of body weight 
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Table 2.4 Mucosa and submucosa mass1-3 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Mucosa   
   Duodenum    0.235 0.0008 0.038 0.129 0.259 0.154 
        7d 0.279 ± 0.030b 0.280 ± 0.029b 0.308 ± 0.029b  
        14d 0.411 ± 0.029a 0.318 ± 0.028b 0.334 ± 0.029ab 
   Jejunum    0.368 0.437 0.315 0.467 0.277 0.381 
        7d 0.481 ± 0.043 0.451 ± 0.043 0.455 ± 0.041  
        14d 0.465 ± 0.041 0.503 ± 0.041 0.436 ± 0.043 
   Ileum    0.306 0.002 0.350 0.232 0.194 0.183 
        7d 0.251 ± 0.038 0.311 ± 0.038 0.314 ± 0.037  
        14d 0.339 ± 0.037 0.358 ± 0.037 0.370 ± 0.037 
   Colon    0.322 0.019 0.088 0.224 0.205 0.182 
        7d 0.401 ± 0.057 0.376 ± 0.061 0.417 ± 0.051  
        14d 0.519 ± 0.057 0.460 ± 0.058 0.417 ± 0.041 
     
Submucosa   
   Duodenum    0.366 0.251 0.066 0.346 0.215 0.248 
        7d 0.155 ± 0.037 0.184 ± 0.037 0.173 ± 0.037  
        14d 0.191 ± 0.037 0.147 ± 0.037 0.142 ± 0.037 
   Jejunum    0.077 0.014 0.347 0.058 0.044 0.037 
        7d 0.140 ± 0.026 0.180 ± 0.026 0.198 ± 0.025  
        14d 0.118 ± 0.025 0.158 ± 0.025 0.151 ± 0.026 
   Ileum    0.391 0.028 0.246 0.359 0.260 0.281 
        7d 0.183 ± 0.031 0.209 ± 0.031 0.198 ± 0.031  
        14d 0.213 ± 0.031 0.218 ± 0.031 0.255 ± 0.031 
   Colon    0.347 0.099 0.101 0.413 0.206 0.275 
        7d 0.553 ± 0.049 0.473 ± 0.049 0.433 ± 0.047  
        14d 0.504 ± 0.048 0.563 ± 0.047 0.545 ± 0.047 
1Data are expressed as mean ± SEM 
2Unit of measure is grams per centimeter of tissue 
3
Within intestinal segment, different superscripts indicate statistically significant differences 
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Table 2.5 Intestinal crypt-villus architecture1-2 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Villus height3   
   Duodenum    0.202 0.016 0.241 0.314 0.093 0.149 
        7d 373 ± 22 381 ± 22 378 ± 21  
        14d 394 ± 21 407 ± 21 446 ± 21 
   Jejunum    0.488 0.134 0.424 0.432 0.491 0.465 
        7d 456 ± 26 458 ± 27 449 ± 26  
        14d 478 ± 27 467 ± 27 487 ± 26 
   Ileum    0.317 0.083 0.356 0.208 0.473 0.299 
        7d 362 ± 27 409 ± 27 376 ± 30  
        14d 407 ± 27 419 ± 30 398 ± 27 
     
Villus width3   
   Duodenum    0.173 0.009 0.236 0.091 0.165 0.097 
        7d 202 ± 8.6 208 ± 8.6 205 ± 8.2  
        14d 207 ± 8.2 231 ± 8.2 224 ± 8.2 
   Jejunum    0.274 0.483 0.333 0.174 0.196 0.155 
        7d 194 ± 7.9 178 ± 8.1 182 ± 7.9  
        14d 188 ± 8.1 184 ± 8.1 182 ± 7.9 
   Ileum    0.469 0.299 0.181 0.369 0.438 0.388 
        7d 165 ± 6.7 153 ± 6.9 163 ± 7.7  
        14d 161 ± 6.7 167 ± 7.9 161 ± 6.9 
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Table 2.5 Continued 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Villus surface 
area4 
  
   Duodenum    0.110 0.003 0.289 0.112 0.046 0.048 
        7d 75,586 ± 6220 79,695 ± 6220 79,559 ± 5955  
        14d 83,027 ± 5955 93,889 ± 5955 99,673 ± 5955 
   Jejunum    0.350 0.127 0.441 0.223 0.290 0.226 
        7d 88,123 ± 5840 80,717 ± 6067 81,491 ± 5840  
        14d 90,269 ± 6067 86,100 ± 6067 88,771 ± 5840 
   Ileum    0.302 0.080 0.420 0.200 0.454 0.332 
        7d 59,611 ± 4240 62,944 ± 4438 61,186 ± 4885       
        14d 65,962 ± 4240 70,284 ± 5198 63,365 ± 4438       
          
Crypt Depth3          
   Duodenum    0.304 0.101 0.427 0.167 0.248 0.171 
        7d 562 ± 25 590 ± 25 575 ± 24       
        14d 588 ± 24 597 ± 24 601 ± 24       
   Jejunum    0.358 0.086 0.023 0.322 0.372 0.467 
        7d 520 ± 32ab 561 ± 32a 556 ± 32a       
        14d 546 ± 32ab 539 ± 32ab 486 ± 32b       
   Ileum    0.269 0.310 0.396 0.162 0.219 0.159 
        7d 310 ± 27 349 ± 27 328 ± 29       
        14d 316 ± 27 345 ± 29 349 ± 27       
   Colon    0.111 0.013 0.086 0.044 0.277 0.090 
        7d 424 ± 23 467 ± 24 463 ± 23       
        14d 483 ± 23 496 ± 23 463 ± 23       
1Data are expressed as mean ± SEM 
2
Within intestinal segment, different superscripts indicate statistically significant differences 
3Unit of measure is microns 
4Unit of measure is microns squared 
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Table 2.6 Epithelial Cell Proliferation at day 71-3 
 Virginiamycin (mg/kg) P-value 
 0 11 Txt 
Duodenum 39.6 ± 2.5 44.3 ± 3.1 0.055 
Jejunum 33.2 ± 1.9 36.6 ± 2.0 0.130 
Ileum 25.9 ± 1.9b 29.9 ± 1.9a 0.003 
Colon 51.8 ± 3.9 59.3 ± 4.0 0.144 
1Data are expressed as mean ± SEM 
2Unit of measure is number of proliferating cell nuclear antigen positive cells per crypt 
3Within intestinal segment, different superscripts indicate statistically significant differences 
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Table 2.7 Cellular RNA Concentration per Cell1-2 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Duodenum    0.320 0.061 0.401 0.188 0.305 0.211 
        7d 3.37 ± 1.0 4.20 ± 1.0 4.20 ± 1.0  
        14d 2.66 ± 1.0 3.70 ± 1.0 2.85 ± 1.0 
Jejunum    0.247 0.083 0.233 0.135 0.188 0.130 
        7d 0.314 ± 0.027 0.365 ± 0.018 0.369 ± 0.022  
        14d 0.321 ± 0.026 0.337 ± 0.023 0.323 ± 0.031 
Ileum    0.495 0.110 0.166 0.493 0.461 0.481 
        7d 0.265 ± 0.037 0.292 ± 0.038 0.270 ± 0.037  
        14d 0.262 ± 0.037 0.234 ± 0.037 0.268 ± 0.037 
Colon    0.404 0.266 0.246 0.311 0.281 0.271 
        7d 1.20 ± 1.5 1.48 ± 1.9 1.41 ± 1.6  
        14d 1.46 ± 2.1 1.38 ± 1.8 1.48 ± 1.5 
1Data are expressed as mean ± SEM 
2Unit of measure is milligram of RNA per milligram of DNA 
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Table 2.8 Cellular Protein Concentration1-2 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
   Duodenum    0.337 0.103 0.338 0.279 0.212 0.215 
        7d 57.0 ± 9.5 64.5 ± 9.5 70.9 ± 9.3  
        14d 55.0 ± 9.3 58.1 ± 9.3 55.8 ± 9.3 
   Jejunum    0.473 0.111 0.145 0.477 0.383 0.418 
        7d 8.98 ± 0.70 9.13 ± 0.58 9.83 ± 0.69  
        14d 9.05 ± 0.52 9.00 ± 0.68 8.70 ± 0.57 
   Ileum    0.385 0.281 0.250 0.437 0.310 0.421 
        7d 7.63 ± 0.61 8.04 ± 0.63 8.10 ± 0.61  
        14d 7.80 ± 0.61 7.14 ± 0.61 8.12 ± 0.61 
   Colon    0.404 0.179 0.477 0.289 0.313 0.275 
        7d 32.8 ± 2.5 31.8 ± 2.6 32.0 ± 2.5  
        14d 34.9 ± 2.5 32.9 ± 2.5 33.1 ± 2.5 
1Data are expressed as mean ± SEM 
2Unit of measure is milligram of protein per milligram of DNA 
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Table 2.9 Tissue DNA Concentration1-2 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
   Duodenum    0.435 0.011 0.299 0.357 0.323 0.318 
        7d 1.35 ± 0.22 1.20 ± 0.22 1.05 ± 0.22  
        14d 1.55 ± 0.22 1.50 ± 0.22 1.60 ± 0.22 
   Jejunum    0.487 0.230 0.061 0.414 0.461 0.428 
        7d 9.68 ± 0.76 9.99 ± 0.63 9.09 ± 0.66  
        14d 9.97 ± 0.62 9.29 ± 0.65 10.4 ± 0.69 
   Ileum    0.492 0.413 0.053 0.465 0.433 0.441 
        7d 11.5 ± 1.1 9.83 ± 1.1 10.0 ± 1.1  
        14d 9.53 ± 1.1 10.9 ± 1.1 10.5 ± 1.1 
   Colon    0.425 0.214 0.287 0.327 0.298 0.287 
        7d 1.62 ± 0.15 1.43 ± 0.15 1.46 ± 0.15  
        14d 1.46 ± 0.15 1.53 ± 0.15 1.48 ± 0.15 
1Data are expressed as mean ± SEM 
2Unit of measure is milligram of DNA per milligram of tissue 
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Table 2.10 Intestinal disaccharidase activity1-3 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Sucrase Activity   
   Duodenum    0.269 0.003 0.039 0.200 0.147 0.138 
        7d 59.7 ± 49ab 33.5 ± 27c 38.8 ± 32bc  
        14d 58.6 ± 49ab 76.5 ± 63a 61.4 ± 51a 
   Jejunum    0.442 0.099 0.124 0.342 0.315 0.314 
        7d 3243 ± 1260 2853 ± 1143 2672 ± 1055  
        14d 2804 ± 1100 3622 ± 1419 3974 ± 1656 
   Ileum    0.362 0.041 0.443 0.452 0.277 0.389 
        7d 87.3 ± 36 78.0 ± 33 102 ± 42  
        14d 63.1 ± 26 64.6 ± 27 84.6 ± 35 
   Colon    0.180 0.368 0.092 0.099 0.452 0.190 
        7d 11.3 ± 50 83.0 ± 40 79.0 ± 40  
        14d 10.3 ± 50 64.0 ± 30 13.8 ± 70 
     
Lactase Activity   
   Duodenum    0.462 0.086 0.086 0.380 0.445 0.347 
        7d 61.0 ± 28 46.0 ± 21 52.0 ± 25  
        14d 51.6 ± 24 71.7 ± 34 69.0 ± 33 
   Jejunum    0.479 0.227 0.297 0.451 0.391 0.407 
        7d 2831 ± 813 3399 ± 962 2721 ± 814  
        14d 2514 ± 745 2248 ± 127 3033 ± 1147 
   Ileum    0.463 0.231 0.130 0.467 0.396 0.457 
        7d 7.1 ± 1.4 5.2 ± 1.6 6.6 ± 1.3  
        14d 4.9 ± 2.3 7.0 ± 1.4 4.6 ± 1.8 
   Colon    0.349 0.272 0.233 0.361 0.322 0.475 
        7d 22.3 ± 7.0 23.1 ± 8.0 17.4 ± 6.0  
        14d 18.3 ± 6.0 20.3 ± 7.0 19.7 ± 6.0 
1Data are expressed as mean ± SEM 
2Unit of measure is µmol hydrolyzed substrate per hour (unit (U) of activity) per gram of protein 
3
Within intestinal segment, different superscripts indicate statistically significant differences 
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Table 2.11 Basal ion transport1 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Short circuit current2   
   Duodenum    0.293 0.277 0.202 0.204 0.171 0.151 
        7d 13.8 ± 5.5 16.0 ± 6.6 13.7 ± 5.1  
        14d 27.7 ± 11 9.30 ± 4.7 18.7 ± 9.5 
   Jejunum    0.450 0.130 0.436 0.391 0.335 0.342 
        7d 12.1 ± 5.5 11.8 ± 6.7 14.8 ± 5.5  
        14d 14.3 ± 7.4 19.2 ± 8.2 18.5 ± 7.6 
   Ileum    0.375 0.424 0.423 0.331 0.233 0.253 
        7d 7.88 ± 6.1 12.1 ± 7.5 13.0 ± 5.5  
        14d 10.9 ± 4.4 11.3 ± 4.4 12.5 ± 4.1 
   Colon    0.115 0.453 0.129 0.092 0.061 0.056 
        7d 21.6 ± 14 22.0 ± 14 28.1 ± 16  
        14d 11.6 ± 14 31.1 ± 14 30.8 ± 15 
     
Transmucosal 
Resistance3 
  
   Duodenum    0.153 0.311 0.185 0.268 0.208 0.462 
        7d 100 ± 30 71.8 ± 15 114 ± 20  
        14d 92.5 ± 21 98.9 ± 21 110 ± 36 
   Jejunum    0.423 0.033 0.427 0.349 0.296 0.293 
        7d 95.1 ± 18 99.9 ± 21 113 ± 17  
        14d 122 ± 19 132 ± 21 127 ± 32 
   Ileum    0.382 0.111 0.126 0.498 0.269 0.359 
        7d 103 ± 24 128 ± 20 135 ± 25  
        14d 148 ± 22 121 ± 25 144 ± 20 
   Colon    0.398 0.440 0.311 0.299 0.476 0.397 
        7d 35.6 ± 17 40.0 ± 19 41.6 ± 20  
        14d 41.1 ± 20 44.7 ± 21 34.5 ± 16 
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Table 2.11 Continued 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Potential 
Difference4 
         
   Duodenum    0.155 0.394 0.411 0.095 0.468 0.224 
        7d 1.49 ± 0.64 0.446 ± 0.13 1.40 ± 0.61  
        14d 1.27 ± 0.54 0.861 ± 0.37 1.45 ± 0.61 
   Jejunum    0.298 0.035 0.285 0.238 0.184 0.175 
        7d 1.40 ± 0.82 1.27 ± 0.61 2.03 ± 0.61  
        14d 1.82 ± 0.76 3.51 ± 1.4 3.06 ± 1.0 
   Ileum    0.209 0.066 0.180 0.094 0.343 0.116 
        7d 0.761 ± 1.1 1.30 ± 1.1 1.28 ± 1.1  
        14d 1.49 ± 1.1 3.35 ± 1.8 1.27 ± 1.1 
   Colon    0.048 0.170 0.107 0.265 0.017 0.046 
        7d 0.744 ± 0.14 0.583 ± 0.16 1.78 ± 0.63  
        14d 0.488 ± 0.26 0.946 ± 0.25 0.771 ± 0.09 
        Mean5-6 0.603 ± 0.18b 0.743 ± 0.13ab 1.17 ± 0.32a  
1Data are expressed as mean ± SEM 
2Unit of measure is µA/cm2 
3Unit of measure is Ω●cm2 
4Unit of measure is millivolts 
5Means pooled within treatment 
6Different superscripts indicate statistically significant differences 
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Table 2.12 Nutrient transport1-3 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Glucose transport   
   Duodenum    0.075 0.236 0.310 0.032 0.097 0.025 
        7d 0.637 ± 0.49 1.05 ± 0.63 0.713 ± 0.57  
        14d 0.549 ± 0.44 1.42 ± 0.81 1.04 ± 0.61 
   Jejunum    0.123 0.028 0.186 0.094 0.078 0.045 
        7d 2.09 ± 1.4 2.06 ± 1.3 2.87 ± 1.5  
        14d 2.41 ± 1.6 5.85 ± 2.5 6.33 ± 4.1 
   Ileum    0.312 0.136 0.206 0.174 0.335 0.215 
        7d 18.8 ± 11 11.0 ± 8.4 19.9 ± 11  
        14d 15.6 ± 9.9 11.9 ± 9.1 10.2 ± 8.4 
   Colon    0.260 0.443 0.119 0.131 0.335 0.169 
        7d 1.34 ± 0.85 2.80 ± 1.4 1.00 ± 0.75  
        14d 1.30 ± 0.94 1.58 ± 1.1 2.31 ± 1.4 
   
Glutamine transport   
   Duodenum    0.187 0.007 0.286 0.083 0.352 0.143 
        7d 2.36 ± 1.0 4.71 ± 1.8 2.53 ± 0.92  
        14d 1.35 ± 0.65 1.89 ± 0.73 1.67 ± 0.82 
   Jejunum    0.010 0.088 0.356 0.006 0.038 0.002 
        7d 1.90 ± 0.60 4.61 ± 2.1 2.75 ± 1.0  
        14d    0.964 ± 0.25 2.65 ± 0.71 2.68 ± 1.4 
        Mean4 1.39 ± 0.28b 3.56 ± 0.95a 2.72 ± 0.81a  
   Ileum    0.096 0.352 0.327 0.280 0.130 0.425 
        7d 5.06 ± 2.1 4.97 ± 1.8 4.03 ± 1.4  
        14d 4.20 ± 1.5 6.03 ± 2.4 2.93 ± 1.3 
   Colon    0.449 0.048 0.104 0.459 0.368 0.450 
        7d 5.66 ± 2.3 9.14 ± 4.5 9.02 ± 2.9  
        14d 6.84 ± 2.5 3.47 ± 2.0 5.36 ± 2.2 
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Table 2.12 Continued 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Arginine 
transport 
  
   Duodenum    0.470 0.201 0.347 0.373 0.402 0.364 
        7d 0.643 ± 0.18 0.833 ± 0.29 0.870 ± 0.32  
        14d 1.01 ± 0.34 0.957 ± 0.41 0.873 ± 0.44 
   Jejunum    0.046 0.338 0.404 0.025 0.084 0.014 
        7d 0.768 ± 0.19 1.49 ± 0.52 1.05 ± 0.38  
        14d 0.515 ± 0.19 1.17 ± 0.62 1.24 ± 0.82 
        Mean4 0.630 ± 0.13b 1.32 ± 0.38a 1.14 ± 0.42ab  
   Ileum    0.356 0.283 0.042 0.326 0.245 0.250 
        7d 4.06 ± 2.4a 1.44 ± 1.2c 2.20 ± 1.6bc  
        14d 1.53 ± 1.1c 3.12 ± 2.1b 1.77 ± 1.7bc 
   Colon    0.360 0.409 0.329 0.367 0.335 0.482 
        7d 1.93 ± 0.79 2.13 ± 0.91 2.61 ± 1.1  
        14d 2.61 ± 1.1 1.57 ± 0.65 3.16 ± 1.4 
1Data are expressed as mean ± SEM 
2Unit of measure is µA/cm2 
3Within intestinal segment, different superscripts indicate statistically significant differences 
4Means pooled within treatment 
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Table 2.13 Serotonin and Carbachol induced-chloride secretion1-3 
 
Virginiamycin (mg/kg) 
P-value 
Mixed model Contrast 
0 11 27.5 Txt Time Interaction 0 vs. 11 0 vs. 27.5 0 vs. txt 
Serotonin   
 Duodenum    0.122 0.087 0.318 0.105 0.308 0.279 
        7d 0.456 ± 0.31 0.917 ± 0.47 0.514 ± 0.34  
        14d 0.909 ± 0.42 1.06 ± 0.48 0.643 ± 0.36 
  Jejunum    0.028 0.088 0.090 0.060 0.208 0.292 
        7d 1.62 ± 0.87 3.96 ± 1.5 0.828 ± 0.42  
        14d 1.15 ± 0.51 1.46 ± 0.64 1.12 ± 0.48 
        Mean4 1.37 ± 0.46ab 2.56 ± 0.68a 0.970 ± 0.30b 
  Ileum    0.381 0.326 0.184 0.238 0.428 0.301 
        7d 1.28 ± 0.94 0.916 ± 0.48 0.789 ± 0.35  
        14d 0.621 ± 0.25 1.86 ± 1.0 1.28 ± 1.0 
  Colon    0.490 0.384 0.311 0.454 0.472 0.489 
        7d 1.50 ± 0.87 1.92 ± 0.89 1.70 ± 0.81  
        14d 1.82 ± 0.91 1.24 ± 0.78 1.74 ± 0.81 
   
Carbachol   
 Duodenum    0.200 0.107 0.109 0.258 0.238 0.496 
        7d 1.56 ± 0.66 2.58 ± 1.3 2.11 ± 5.2  
        14d 1.96 ± 0.77 1.78 ± 0.77 0.974 ± 0.42 
  Jejunum    0.423 0.033 0.427 0.349 0.296 0.293 
        7d 18.7 ± 8.5 97.6 ± 47.5 8.13 ± 3.6  
        14d 11.8 ± 5.3 16.2 ± 7.4 11.5 ± 5.2 
  Ileum    0.352 0.406 0.017 0.326 0.338 0.485 
        7d 1.71 ± 0.68ab 0.727 ± 0.17bc 0.982 ± 0.33abc  
        14d 0.703 ± 0.14c 2.78 ± 1.0a 0.780 ± 0.17abc 
  Colon    0.486 0.382 0.079 0.432 0.482 0.472 
        7d 7.71 ± 3.4 14.3 ± 6.5 8.44 ± 3.7  
        14d 11.6 ± 5.2 5.42 ± 2.4 11.1 ± 5.0 
1Data are expressed as mean ± SEM 3Within intestinal segment, different superscripts indicate statistically significant differences 
2Unit of measure is µA/cm2   4Means pooled within treatment
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Table 2.14 Description of the major factors obtained by principal component analysis 
(PCA) of thirty-seven variables characterizing the gut structure and function of pigs in 
control and 11 mg/kg virginiamycin groups at day 71-2  
Factor 1 2 3 4 5 6 7 
Variance explained (%) 17.8 14.1 12.3 9.6 7.6 6.3 5.1 
Cumulative (%) 17.8 31.9 44.2 53.8 61.4 67.7 72.8 
Loadings of variables3        
Duodenum resistance 0.92       
Jejunum DNA -0.79       
Jejunum resistance 0.60    0.43   
Ileum glucose transport 0.53       
Ileum 5HT 0.87       
Colon arginine transport 0.92       
Average daily gain  -0.74 0.43     
SI length  0.78      
Duodenum RNA  0.72      
Duodenum glutamine transport  0.55    -0.41  
Jejunum submucosal mass  -0.43      
Colon length  0.82      
Duodenum submucosal mass  -0.40 0.41 0.41    
Jejunum crypt depth   0.52 -0.46 0.47   
Ileum crypt depth   0.73  0.41   
Ileum PCNA   0.79     
Colon mass   0.71     
Colon DNA   -0.79     
Colon glutamine transport   0.53     
Duodenum potential difference    0.92    
Jejunum sucrase activity    0.83    
Jejunum PCNA    -0.57    
Colon potential difference    0.89    
Jejunum Isc     0.75   
Ileum villus height     0.53   
Colon crypt depth     0.80   
Colon PCNA     0.75   
Duodenum sucrase activity      0.81  
Duodenum lactase activity      0.83  
Jejunum lactase activity      0.71  
Colon submucosal mass      -0.48  
Colon Isc      0.59  
Duodenum CCH       0.86 
Ileum protein       0.75 
Ileum RNA       -0.74 
Jejunum glutamine transport4        
Colon lactase activity4        
1Abbreviations: 5HT, serotonin induced chloride secretion; SI, small intestine; PCNA, 
proliferating cell nuclear antigen; Isc, short circuit current; CCH, carbachol induced 
chloride secretion.  
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2Extraction method: PCA; rotation method: varimax with Kaiser normalization 
3Only correlations with │r│ ≥ 0.40 are indicated. 
4Variables included in final analysis but did not load on the first 7 factors 
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Table 2.15 Description of the major factors obtained by principal component analysis 
(PCA) of thirty-four variables characterizing the gut structure and function of pigs in 
control and 11 mg/kg virginiamycin groups at day 141-3 
Factor 1 2 3 4 5 6 7 
Variance explained (%) 16.6 12.2 10.6 9.8 7.9 7.2 6.5 
Cumulative (%) 16.6 28.8 39.4 49.2 57.1 64.3 70.8 
Loadings of variables4        
Duodenum arginine transport 0.84       
Jejunum protein -0.55       
Jejunum arginine transport 0.84       
Ileum crypt depth 0.84       
Ileum sucrase activity 0.61       
Ileum lactase activity 0.58       
Ileum potential difference -0.68       
Duodenum crypt depth  0.73      
Jejunum crypt depth  0.86      
Jejunum 5HT  0.47      
Colon glucose transport  0.77     0.41 
Duodenum submucosal mass   0.79     
Jejunum resistance   0.49  0.40 0.49  
Colon glutamine transport   0.75     
Colon arginine transport   0.78     
Feed per unit of gain    0.84    
SI length    0.76    
SI mass    0.88    
Duodenum lactase activity  -0.58   0.62   
Jejunum lactase activity     0.75   
Colon potential difference     0.90   
Duodenum resistance      0.76  
Duodenum Isc      -0.47  
Duodenum glucose transport  0.43    0.53  
Jejunum sucrase activity     0.45 0.51  
Colon mass      -0.79  
Ileum submucosal mass       -0.42 
Ileum villus height       -0.42 
Ileum resistance       -0.80 
Ileum CCH       0.85 
Duodenum glutamine transport5        
Colon RNA5        
Colon sucrase activity5        
Colon 5HT5        
1Abbreviations: 5HT, serotonin induced chloride secretion; SI, small intestine; Isc, short circuit 
current; CCH, carbachol induced chloride secretion 
2Extraction method: PCA; rotation method: varimax with Kaiser normalization  
3Factor scores for control and 11 mg/kg groups are significantly different (factor 5: p=0.015; factor 7: 
p=0.050) 
4Only correlations with │r│ ≥ 0.40 are indicated 
5Variables included in final analysis but did not load on the first 7 factors 
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Table 2.16 Summary of factors 5 and 7 of the Principal Component Analysis (PCA) completed 
with data from control and 11 mg/kg virginiamycin groups at day 141-2  
Control  (-)
3 
11 mg/kg virginiamycin (+)
4 
Ileal submucosal mass 
Ileal mucosal mass 
Duodenal lactase activity 
Ileal villus height Duodenal glucose transport
5 
Ileal resistance Jejunal disaccharidase activity 
 Jejunal resistance 
 Ileal carbachol-induced chloride secretion
5 
Ileal serotonin-induced chloride secretion 
 Colonic potential difference
5 
Colonic short-circuit current 
1
Factors 5 and 7 of PCA 2 discriminate between control and 11 mg/kg virginiamycin-fed 
pigs 
2
Ileal mucosal mass, ileal serotonin-induced chloride secretion, and colonic short-circuit 
current were not included in the final PCA but were significantly correlated with the 
variable within the same cell in the table and, therefore, can be used in the interpretation 
3
Factor scores for control were negative 
4
Factor scores for 11 mg/kg virginiamycin were positive 
5
Variable significant by split-plot or contrast analysis 
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Figure 2.1 Duodenal mucosal mass expressed as grams per centimeter of 
tissue. Data are expressed as mean ± standard error measurement (SEM). 
Different letters above bars indicate a statistically significant difference. 
In the duodenum, mucosal mass increased over time in the control pigs, 
but it did not in pigs fed diets supplemented with virginiamycin resulting 
in less mucosal mass in the duodenum in the 11 mg/kg virginiamycin 
group at day fourteen (p=0.038).   
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Figure 2.2 Jejunal submucosal mass expressed as grams per centimeter 
of tissue. Data are expressed as pooled treatment mean ± (SEM).  In the 
jejunum, virginiamycin-fed pigs had more submucosal mass compared 
with control when virginiamycin groups were contrasted with control 
(p=0.037). 
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Figure 2.3 Duodenal villus surface area for control, 11 mg/kg, and 27.5 
mg/kg virginiamycin. Magnification of 5X with hematoxylin and eosin 
stain. Villus surface area was greater in the duodenum of virginiamycin-
fed pigs compared with control when virginiamycin groups were 
contrasted with control (p=0.048). 
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Figure 2.4 Crypt depth in the jejunum. Data are expressed as mean ± 
SEM. Different letters above bars indicate a statistically significant 
difference.  Crypt depth decreased in pigs fed the diet supplemented with 
27 mg/kg of virginiamycin over time in the jejunum (p=0.023) 
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Figure 2.5 Colonic crypt depth. Data are expressed as pooled treatment 
mean ± (SEM).  Pigs fed diets containing 11 mg/kg of virginiamycin had 
deeper crypts in the colon compared with control when the 11 mg/kg 
group was contrasted with control (p=0.044). 
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Figure 2.6 Ileal epithelial cell proliferation at 7 days in control and 11 
mg/kg virginiamycin-fed pigs, as measured by quantifying the number of 
proliferating cell nuclear antigen (PCNA)-positive cells per crypt.  Black 
arrows indicate PCNA positive cells.  Magnification of 5X with VIP 
stain.  Virginiamycin treatment increased the number of PCNA-positive 
cells per crypt in the ileum at seven days compared with control 
(p=0.003). 
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Figure 2.7 Sucrase activity in the duodenum expressed as unit of activity 
per gram of protein. Data are expressed as mean ± SEM. Different letters 
above bars indicate a statistically significant difference. Sucrase activity 
in the duodenum was lower in the 11 mg/kg virginiamycin group 
compared with control at day seven, but it increased over time in the 
virginiamycin groups (p=0.039). 
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Figure 2.8 Potential difference in the colon. Data are expressed as 
pooled treatment mean ± SEM.  Different letters above bars indicate a 
statistically significant difference. Potential difference was increased in 
the colon with the highest virginiamycin treatment compared with 
control (p=0.048). 
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Figure 2.9 Sodium-coupled glucose transport in the duodenum. Data are 
expressed as pooled treatment mean ± SEM.  Virginiamycin treatment 
increased glucose transport in the duodenal mucosa compared with 
control when virginiamycin treatments were contrasted with control 
(p=0.025).  
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Figure 2.10 Sodium-coupled glucose transport in the jejunum. Data are 
expressed as pooled treatment mean ± SEM.  Virginiamycin treatment 
increased glucose transport in the jejunum compared with control when 
virginiamycin treatments were contrasted with control (p=0.045). 
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Figure 2.11 Electrogenic glutamine transport in the jejunum. Data are 
expressed as pooled treatment mean ± SEM. Different letters above bars 
indicate a statistically significant difference. Virginiamycin treatment 
increased electrogenic glutamine transport in the jejunual mucosa 
compared with control (p=0.010). 
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Figure 2.12 Electrogenic arginine transport in the jejunum. Data are 
expressed as pooled treatment mean ± SEM. Different letters above bars 
indicate a statistically significant difference. Jejunal arginine transport 
was significantly greater in the 11 mg/kg virginiamycin group compared 
with control (p=0.046). 
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Figure 2.13 Electrogenic arginine transport in the ileum. Data are 
expressed as mean ± SEM. Different letters above bars indicate a 
statistically significant difference. Pigs consuming diets supplemented 
with virginiamycin had less ileal arginine transport compared with 
control pigs at day seven. Ileal arginine transport decreased over time in 
control pigs while increasing over time in the pigs fed diets containing 
11 mg/kg of virginiamycin resulting in more arginine transport in the 
ileum of pigs fed diets supplement with 11 mg/kg of virginiamycin diets 
compared with control at day fourteen (p=0.042). 
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Figure 2.14 Carbachol induced chloride secretion (CCH) in the ileum. 
Data are expressed as mean ± SEM. Different letters above bars indicate 
a statistically significant difference. Ileal carbachol induced chloride 
secretion was decreased in the control pigs, but it increased in pigs 
consuming the diet supplemented with 11 mg/kg of virginiamycin at day 
fourteen compared with day seven.  This resulted in greater carbachol 
induced chloride secretion in the 11 mg/kg virginiamycin group at day 
fourteen compared with control (p=0.017). 
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Figure 2.15 Virginiamycin impacts on intestinal structure and function observed in our study. 
Duodenum 
- ↓Mucosal mass 
- ↑Villus surface area 
- ↓Sucrase activity 
- ↑Glucose transport 
Jejunum 
- ↑Submucosal mass 
- ↑Glucose transport 
- ↑Glutamine transport 
- ↑Arginine transport 
Ileum 
- ↑Proliferation 
- ↓↑Arginine transport 
- ↑Carbachol-induced 
chloride secretion 
Colon 
- ↑Crypt depth 
- ↑Potential difference 
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Chapter 3: Future Directions 
  In-feed antibiotics play a large role in animal health and production by improving 
performance and feed efficiency and, thus, increasing affordable pork supply.  The safety of in-
feed antibiotics has come into question regarding human health.  Understanding how antibiotics 
promote growth will help determine the safety of their use and provide a knowledge basis for 
alternatives if the use of antibiotics for growth promotion is prohibited.  Therefore, the objective 
of this research was to investigate the structural and functional developments induced in the 
intestine by the consumption of virginiamycin in grower pigs and to determine how these 
developments may be mechanistically related to the differences in growth. 
 Results of this study demonstrate that virginiamycin impacts functional capacity to a 
greater extent than structural indices.  Pigs fed diets supplemented with virginiamycin had 
increased absorptive surface area in the duodenum but significant increases in nutrient transport 
along the entire small intestine.  Future research is needed to ascertain the mode of action of 
virginiamycin in grower pigs and investigate the relationship between increased nutrient 
transport and virginiamycin.   
Future direction for this line of research includes investigating: 
1) cellular kinetics in the intestinal epithelium  
2) nutrient transporters 
3) digestive enzyme activity 
4) immune response markers 
5) microbiota analysis 
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 Future research should focus on the 11 mg/kg level of virginiamycin, because that is the 
level currently approved for growth promotion and feed efficiency in grower pigs.  Grower pigs 
are good subjects to use for investigating the effects of antibiotics on growth promotion and feed 
efficiency because growth responses are greater than in finisher pigs without the added dynamics 
of weaning-associated changes in weaning piglets. 
 Increased proliferation was observed at seven days in the ileum without increases in the 
crypt-villus axis.  Future work should investigate if there is a subsequent increase in apoptosis at 
day seven.  If apoptosis is not increased at this time point, it may be necessary to investigate time 
points beyond fourteen days to determine if structural changes occur along the crypt-villus axis 
at later time points.  Additionally, cellular differentiation should be investigated.  Immature, 
rapidly proliferating cells at day seven but more mature, differentiated cells by day fourteen may 
explain the unique functional response observed in the ileum with virginiamycin. 
Nutrient transport was significantly increased along the small intestine with 
virginiamycin.  However, increased absorptive surface area was not observed beyond the 
duodenum.  This suggests that pigs fed diets supplemented with virginiamycin may have up-
regulation of nutrient transporters or increased enzyme activity associated with digestion and 
absorption.  Sucrase and lactase activities were not greatly impacted by virginiamycin, but future 
studies should investigate additional digestive enzymes such as maltase and peptidase activities.  
Nutrient transporter mRNA expression should be quantified to investigate, in more detail, the 
molecular basis for treatment differences in functional indices. 
Decreased mucosal mass in the duodenum and increased carbachol induced chloride 
secretion in the ileum may support the immune response theory proposed by Niewold (2007).  
Future research should investigate immune response markers of innate and acquired immunity.  
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Assessing intestinal and plasma cytokines and antibody response may provide further support to 
this mechanism.  Pro-inflammatory cytokines are early mediators produced in response to tissue 
damage and may be impacted by in-feed antibiotics.  Virginiamycin has been shown to enhance 
systemic antibody response to soluble antigens in chickens (Brisbin et al., 2008).  Lymphocyte 
stimulation assays would also provide insight to the effect of virginiamycin on the immune 
response. 
 Mucins contribute to the health of the intestinal epithelium by producing a mucus layer to 
protect the tissue through lubrication and preventing bacterial adhesion.  Van Leeuwen and 
colleagues (2002) observed a significant increase in crypt goblet cells in the jejunum of piglets 
fed virginiamycin supplemented diets.  Studying goblet cells and mucins in the intestinal lumen 
will provide insight on the effect of virginiamycin on this protection mechanism. 
The most widely-accepted mechanism of action for growth promotion via antibiotics is 
the effect on the microbiota.  The intestinal microbial populations greatly impact the intestinal 
environment and likely play a role in several of the other proposed mechanisms.  Previous 
research has shown that virginiamycin impacts the microbial population in the intestinal tract of 
pigs.  However, those studies have been done with varying amounts of the antibiotic, many of 
them much higher than the current approved level for growth promotion in swine.  Future studies 
should include analysis of the intestinal microbiota in grower pigs fed diets supplemented with 
11 mg/kg of virginiamycin.  Microbial analysis should be included with nutrient transport studies 
and the aforementioned variables to gain a cohesive understanding of the mechanisms behind 
antibiotic growth promotion. 
Overall, the future directions of this research would be aimed at unveiling the 
mechanisms by which virginiamycin promotes faster weight gain and feed efficiency in pigs.   
90 
 
Understanding how virginiamycin works in grower pigs will provide an evidenced-based 
working knowledge from which regulatory decisions can be made on the judicious and prudent 
use of antibiotics in food-producing animals.  In the event that the United States decides to ban 
the use of antibiotics for growth promotion in animals, alternative strategies are needed to 
maintain the level of uniform performance seen with sub-therapeutic levels of antibiotics.  A ban 
on antibiotic use in pigs for growth promotion, without an adequate alternative or change in 
practice, may lead to decreased pork production and a decline in animal health. 
Antibiotic use for growth promotion has been prohibited in the European Union since 
2006; therefore, the European Union provides a valuable reference for evaluating the impact of 
banning antibiotics and assessing alternative practices.  Improving animal husbandry practices 
can greatly impact animal health and productivity.  A reduction in overcrowding and infection 
control techniques may result in improved animal health and performance.  Depopulation and 
repopulation of farms and commercial feedlots can result in cleaner facilities with lower 
microbial loads.  Increasing the weaning age of piglets may also improve the health and 
performance of pigs.  Early weaned piglets have been associated with inconsistent growth rates, 
abnormal feed intake, higher cortisol concentrations, and decreased cellular immune reactivity 
(Johnson et al., 2013).  In Europe, as of the beginning of 2013, piglets are not to be weaned at 
less than 28 days of age.  The law also states that “…piglets may be weaned up to seven days 
earlier if they are moved into specialized housings which are emptied and thoroughly cleaned 
and disinfected before the introduction of a new group…” (Defra, 2011).  This practice was 
adopted in the European Union to produce healthier piglets, increase survival post-weaning, and 
increase the number of live pigs per sow per year. 
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In addition to improve husbandry practices, dietary alternatives to antibiotics have been 
proposed.  In-feed enzymes may be added to feed to help break down certain components of the 
feed to improve digestion.  Probiotics and prebiotics have also been proposed as alternative to 
antibiotics for growth promotion and there is increasing evidence showing the effects of these on 
pigs, primarily regarding intestinal adaptation.  Proposed mechanisms by which probiotics work 
are similar to some of the proposed mechanisms of antibiotics, including improving microbial 
balance in the gut, impacting the immune response, and influencing intestinal metabolic 
activities.  Prebiotics, such as fructooligosaccharides, have been postulated to enhance growth 
responses in livestock.  Zinc and copper have also been investigated as alternatives to in-feed 
antibiotics.  Understanding the mechanisms behind virginiamycin may lead to selection of 
alternatives that can mimic the growth performance effects of virginiamycin. 
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